# PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

## PCT

### NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Commissioner
US Department of Commerce
United States Patent and Trademark Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

| | |
|---|---|
| **Date of mailing** (day/month/year)<br>24 April 2001 (24.04.01) | |
| **International application No.**<br>PCT/AU00/00980 | **Applicant's or agent's file reference**<br>92767 |
| **International filing date** (day/month/year)<br>16 August 2000 (16.08.00) | **Priority date** (day/month/year)<br>16 August 1999 (16.08.99) |
| **Applicant**<br>COOK, David, Ian et al | |

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:

01 March 2001 (01.03.01)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

| | |
|---|---|
| **The International Bureau of WIPO**<br>**34, chemin des Colombettes**<br>**1211 Geneva 20, Switzerland** | Authorized officer<br>Nestor Santesso |
| Facsimile No.: (41-22) 740.14.35 | Telephone No.: (41-22) 338.83.38 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00980

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl. ⁷: C12N 15/12; A61K 38/16, 48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
SEE ELECTRONIC DATABASE BOX BELOW

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
SEE ELECTRONIC DATABASE BOX BELOW

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
See extra sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| PX | Takesono, A. et al (1999) "Receptor-independent activators of heterotrimeric G-protein signaling pathways" J. Biol. Chem. 274(47), pages 33202-5. See the entire document. | 28-32, 40, 45, 46 |
| PX | Ishibashi, H. et al (1999) $Na^+$-$H^+$ exchange in salivary secretory cells is controlled by an intracellular $Na^+$ receptor" Proc. Natl. Acad. Sci. USA 96, pages 9949-53 See the entire document | 3, 5-11, 14-16, 19, 26 |

[X] Further documents are listed in the continuation of Box C [X] See patent family annex

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

| Date of the actual completion of the international search | Date of mailing of the international search report |
|---|---|
| 19 October 2000 | 23 OCT 2000 |
| Name and mailing address of the ISA/AU<br>AUSTRALIAN PATENT OFFICE<br>PO BOX 200, WODEN ACT 2606, AUSTRALIA<br>E-mail address: pct@ipaustralia.gov.au<br>Facsimile No. (02) 6285 3929 | Authorized officer<br>TERRY MOORE<br>Telephone No : (02) 6283 2632 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00980

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| X | Harvey, K.F. et al (1999) "All three WW domains of murine Nedd4 are involved in the regulation of epithelial sodium channels by intracellular $Na^+$" J. Biol. Chem. 274(18), pages 12525-30<br>See in particular the discussion. | 5, 10, 11, 14 |
| X | Komwatana, P. et al (1998) "Activators of epithelial $Na^+$ channels inhibit cytosolic feedback control. Evidence for the existence of a G protein-coupled receptor for cytosolic $Na^+$" J. Membrane Biol. 162, pages 225-32<br>See in particular the discussion and figure 7. | 5, 7, 8, 15, 16 |
| X | Dinudom, A. et al (1998) "Nedd4 mediates control of an epithelial $Na^+$ channel in salivary duct cells by cytosolic $Na^+$" Proc. Natl. Acad. Sci. USA 95, pages 7169-73<br>See in particular the discussion and figure 4. | 5, 6, 10, 11, 14 |
| X | Cook. D.I. et al (1998) "Control of $Na^+$ transport in salivary duct eptithelial cells by cytosolic $Cl^-$ and $Na^+$" Eur. J. Morphology 36, Supplement ++pages 67-73<br>See in particular the summary and figure 8. | 5, 7-9, 14, 16 |
| X | Symons, J.D. et al (1998) "Na-H exchange inhibition with cariporide limits functional impairment caused by repetitive ischemia" J. Cardiovascular Pharmacology 32, pages 853-62<br>See the entire document. | 3, 5, 7 |
| X | EP A 726 254 (MITSUI TOATSU CHEMICALS, INC.) 14 August 1996<br>See page 2, line 120 - page 3, line 3 and claim 10. | 3, 5, 7 |
| X | Komwatana, P. et al (1996) "Cytosolic $Na^+$ controls an epithelial $Na^+$ channel via the $G_o$ guanine nucleotide-binding regulatory protein" Proc. Natl. Acad. Sci. USA 93, pages 8107-11<br>See in particular the discussion and figure 5. | 5, 7, 8, 9, 14, 16 |
| X | EP A 622 356 (SUMITOMO PHARMACEUTICALS CO., LTD.) 2 November 1994<br>See in particular page 3. | 3, 5, 7 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00980

**Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos :
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos :
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

**Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

See extra sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
3, 5-11, 14-16, 19, 26 and 28-47

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

☐ The additional search fees were accompanied by the applicant's protest.

☒ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00980

**Supplemental Box**
(To be used when the space in any of Boxes I to VIII is not sufficient)

**Continuation of Box No: II**

The international application contains 8 separate inventions. These are:

Invention 1. Regulating the activity of NHE1 for normalising cytosolic ion concentration.

Invention 2 Regulating the activity of NHE2 for normalising cytosolic ion concentration.

Invention 3. Regulating the activity of NHE3 for normalising cytosolic ion concentration.

Invention 4. Regulating the activity of $Na^+HCO^-$ cotransporter for normalising cytosolic ion concentration.

Invention 5. Regulation the activity of $Na^+K^+2Cl^-$ cotransporter for normalising cytosolic ion concentration.

Invention 6. Regulating the activity of any $Na^+$ receptor for normalising cytosolic ion concentration.

Invention 7. Sequences 1, 2, 5 and 6 defining GILT sequences and variants.

Invention 8. Sequences 3, 4 and 7 defining SCunique sequences and non-coding regions thereof.

The feature linking inventions 1-6 resides in the regulation of $Na^+$ receptors for therapeutic use. However using epithelial $Na^+$ receptors for therapeutic use is already known. Thus a unity of invention does not exist *a posteriori*.

Inventions 7 and 8 are directed to the identification of new and alternative $Na^+$ receptors. The only common feature between these two inventions and inventions 1-6 is the $Na^+$ receptors. $Na^+$ receptors are already known (see above) and thus no unity exists *a posteriori*. There does not appear to be any common structural feature linking the two sequences defined in inventions 7 and 8 and thus there is no unity of invention *a priori* between these two groups of sequences.

The ISA searched inventions 7 and 8 under one search fee as it does not seem that significant extra effort is involved in combining these two inventions.

An additional search fee was paid and inventions 1-5 were searched under this search fee because it appeared that a single search could be drafted that would encompass all 5 inventions.

As a result the two searches covered the material defined in claims 3, 5-11, 14-16, 19, 26 and 28-47.

**Continuation of Box No: B**

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Medline, CA, GenPept, SwissProt, EMBL, Genbank: Sequences 1-7, keywords: GILT, SCunique, NHE1, NHE2, NHE3, Na+/H+ exchanger, Na+HCO- cotransporter, NaKCl cotransporter, sodium channel, cytosolic, intracellular, inhibition, feedback, regulation

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU00/00980

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

| Patent Document Cited in Search Report | | Patent Family Member | | | | | |
|---|---|---|---|---|---|---|---|
| EP | 622 356 | JP | 7010839 | CN | 1106800 | CA | 2121391 |
| EP | 726 254 | US | 5 627 193 | JP | 8277269 | | |

END OF ANNEX

NJF

# PATENT COOPERATION TREATY

From the:
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

F.B. RICE & CO.
139 Rathdowne Street
CARLTON VIC 3053

## PCT

NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

| | |
|---|---|
| Date of mailing *day/month/year* | 03 JAN 2002 |
| Applicant's or agent's file reference 92767 | IMPORTANT NOTIFICATION |

| International Application No. | International Filing Date | Priority Date |
|---|---|---|
| PCT/AU00/00980 | 16 August 2000 | 16 August 1999 |

Applicant
THE UNIVERSITY OF SYDNEY et al

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.

2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.

3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translations to those Offices.

4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide

| Name and mailing address of the IPEA/AU | Authorized officer |
|---|---|
| AUSTRALIAN PATENT OFFICE<br>PO BOX 200, WODEN ACT 2606, AUSTRALIA<br>E-mail address: pct@ipaustralia.gov.au<br>Facsimile No. (02) 6285 3929 | TERRY MOORE<br>Telephone No. (02) 6283 2632 |

PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

| Applicant's or agent's file reference 92767 | FOR FURTHER ACTION | See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416). |
|---|---|---|
| International Application No. PCT/AU00/00980 | International Filing Date *(day/month/year)* 16 August 2000 | Priority Date *(day/month/year)* 16 August 1999 |

International Patent Classification (IPC) or national classification and IPC

**Int. Cl.** [7] C12N 15/12; A61K 38/16, 48/00

Applicant

THE UNIVERSITY OF SYDNEY et al

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 7 sheets, including this cover sheet.

[X] This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 15 sheet(s).

3. This report contains indications relating to the following items:

| | | |
|---|---|---|
| I | [X] | Basis of the report |
| II | [ ] | Priority |
| III | [ ] | Non-establishment of opinion with regard to novelty, inventive step and industrial applicability |
| IV | [X] | Lack of unity of invention |
| V | [X] | Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement |
| VI | [ ] | Certain documents cited |
| VII | [ ] | Certain defects in the international application |
| VIII | [X] | Certain observations on the international application |

| Date of submission of the demand | Date of completion of the report |
|---|---|
| 1 March 2001 | 19 December 2001 |
| Name and mailing address of the IPEA/AU<br>AUSTRALIAN PATENT OFFICE<br>PO BOX 200, WODEN ACT 2606, AUSTRALIA<br>E-mail address: pct@ipaustralia.gov.au<br>Facsimile No. (02) 6285 3929 | Authorized Officer<br>**TERRY MOORE**<br>Telephone No. (02) 6283 2632 |

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/AU00/00980

## I. Basis of the report

1. With regard to the elements of the international application:*

- [ ] the international application as originally filed.
- [X] the description, pages 9-21, as originally filed,
  pages , filed with the demand,
  pages 7, 8 and 8A , received on 23 August 2001 with the letter of 23 August 2001
  pages 1-6 , received on 5 November 2001 with the letter of 5 November 2001
- [ ] the claims, pages , as originally filed,
  pages , as amended (together with any statement) under Article 19,
  pages , filed with the demand,
  pages 22-27, received on 5 November 2001 with the letter of 5 November 2001
- [ ] the drawings, pages 1/5-5/5, as originally filed,
  pages , filed with the demand,
  pages , received on with the letter of
- [ ] the sequence listing part of the description:
  pages 1-7, as originally filed
  pages , filed with the demand
  pages , received on with the letter of

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language which is:

- [ ] the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- [ ] the language of publication of the international application (under Rule 48.3(b)).
- [ ] the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- [ ] contained in the international application in written form.
- [X] filed together with the international application in computer readable form.
- [ ] furnished subsequently to this Authority in written form.
- [ ] furnished subsequently to this Authority in computer readable form.
- [ ] The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- [ ] The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

4. [ ] The amendments have resulted in the cancellation of:

- [ ] the description, pages
- [X] the claims, Nos. 42-44
- [ ] the drawings, sheets/fig.

5. [ ] This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* *Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).*

** *Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report*

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/AU00/00980

## IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

- [ ] restricted the claims.
- [ ] paid additional fees.
- [ ] paid additional fees under protest.
- [ ] neither restricted nor paid additional fees.

2. [ ] This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

- [ ] complied with.
- [X] not complied with for the following reasons:

The international application comprises 3 separate inventions. These are:

- Invention 1, as defined in claims 1-21, which comprises altering or assessing the activity of components of the inhibitory feedback mechanism controlling the activity of an $Na^+$ transport protein.
- Invention 2, as defined in claims 22-26, 34, 39 and 40, in full and claims 32, 33 and 36-38 in part, which disclose sequences corresponding to the putative intracellular $Na^+$ receptor GILT.
- Invention 3, as defined in claims 27-31, 35 and 41, in full and claims 32, 33 and 36-38 in part, which disclose sequences corresponding to the putative intracellular $Na^+$ receptor SCunique.

Although all three sets of claims relate to components of the inhibitory feedback mechanism controlling the activity of an $Na^+$ transport protein, this feature is known (see D2 and D3). As such this feature does not represent a "special technical feature" and does not confer unity on the three sets of claims.

The ISA agreed to search all three inventions after payment of a second search fee.

Given that all three inventions have been searched, the IPEA has decided to report on all three inventions without requesting further fees.

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

- [X] all parts.
- [ ] the parts relating to claims Nos.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/AU00/00980

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

| | | | |
|---|---|---|---|
| Novelty (N) | Claims | 1-41 | YES |
| | Claims | | NO |
| Inventive step (IS) | Claims | 22-41 | YES |
| | Claims | 1-21 | NO |
| Industrial applicability (IA) | Claims | 1-41 | YES |
| | Claims | | NO |

2. Citations and explanations (Rule 70.7)

The following documents identified in the International Search Report have been considered for the purposes of this report:

D1 Harvey et al (1999) J Biol Chem 274(18), 12525-30
D2 Komwatana et al (1998) J Membrane Biol 162, 225-32
D3 Dinudom et al (1998) Proc Natl Acad Sci USA 95, 7169-73
D4 Cook et al (1998) Eur J Morphology 36, 67-73
D5 Symons et al (1998) J Cardiovascular Pharmacology 32, 853-62
D6 EP 726 254 (MITSUI TOATSU CHEMICALS, INC) 14 August 1996
D7 Komwatana et al (1996) Proc Natl Acad Sci USA 93, 8107-11
D8 EP 622 356 (SUMITOMO PHARMACEUTICALS CO, LTD) 2 November 1994

Takesono et al (1999) J Biol Chem 274(47), 33202-5 and Ishibashi et al (1999) Proc Natl Acad Sci USA 96, 9949-53, cited in the ISR, are not discussed in this opinion because both documents were published after the priority date of the instant application.

The specification discloses further characterisation of an inhibitory feedback mechanism first identified in D7 and further characterised in D1 to D4. The specification discloses two candidates for the intracellular $Na^+$ receptor and indicates that the activities of NHE1, NHE2, NHE3, the $Na^+$-$HCO_3^-$ cotransporter and the $Na^+K^+2Cl$ cotransporter are also controlled by the feedback mechanism.

The amendments filed on 5 November 2001 have limited the scope of the claims such that they now fall within the scope of the search conducted by the ISA. As such, this opinion provides comment on all claims, in contrast to the original opinion that only provided comment on claims 3, 5-11, 14-16, 19, 26 and 28-47.

Novelty (N) and Inventive Step (IS)

As discussed above, D1-D4 and D7 all disclose the inhibitory feedback mechanism and discuss its role in the regulation of the epithelial sodium channel (ENaC) activity. D2-D4 and D7 all discuss the involvement of at least ENaC, Nedd4, ubiquitin ligase and G proteins, and in the case of D2 and D3 the intracellular sodium receptor, in the inhibitory feedback mechanism. In particular D2 and D3 disclose the presence of an intracellular sodium receptor (see figures 7 and 4 respectively) and D1 speculates that there is a further intracellular protein involved in regulation of intracellular sodium concentrations and ubiquitin regulation (see the discussion). As such these citations appear to disclose the same inhibitory mechanism that has been further characterised by the applicants and that is illustrated in figure 5 of the specification.

Continued in supplemental box.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/AU00/00980

## VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 1-21 are not fully supported by the description because the claims are not limited to features that define the invention described in the specification and thereby distinguish between that invention and the prior art.

Prior to the applicant's work on the $Na^+$ inhibitory feedback mechanism it was known that there was such a mechanism and that it regulated the activity of ENaC and cytosolic $Na^+$ composition (see D1-D4 and D7 discussed in Box V). It was also known that there was probably a cytoplasmic $Na^+$ receptor involved in the mechanism, although this receptor had not been identified. It was also known that the activity of G proteins, Nedd4 and ubiquitin ligase modulated the activity of this system (see D2-D4 and D7) and that amiloride was also involved in modulation of cytosolic $Na^+$ concentration at least in part mediated by the feedback mechanism. It appears that the applicant's contribution to this art has been to identify the intracellular receptor as SCunique or GILT and to also identify that this specific feedback mechanism regulates the activity of a range of $Na^+$ transport proteins in addition to ENaC. As such the applicant is entitled to claim the novel aspects of this mechanism; SCunique and GILT. The applicant is also entitled to claim methods of exploiting the $Na^+$ inhibitory feedback mechanism by specifically affecting the activity of $Na^+$ transport proteins other than ENaC, in the context of the $Na^+$ inhibitory feedback mechanism. These two aspects reflect the applicant's contribution to the art and define the features that distinguish the invention described in the specification.

In contrast to this, independent claims 1, 8, 13, 17, 18 and 19 define a method of treating or diagnosing a disease associated with dysfunction of an inhibitory feedback mechanism comprising administration of an agent that blocks said mechanism. As such the claims do not define the specific inhibitory feedback mechanism characterised by the applicant. The claims simply define any inhibitory feedback mechanism and do not define a feedback mechanism that is the mechanism controlling the activity of ENaC, NHE1, NHE2, NHE3, the $Na^+$-$HCO_3^-$ cotransporter and the $Na^+K^+2Cl^-$ cotransporter and involving the activity of the intracellular $Na^+$ receptor GILT or SCunique. It is these features that characterise and distinguish the applicant's feedback mechanism from any other feedback mechanism that may also work to control the activity of $Na^+$ transport proteins.

In addition, the claimed methods are not limited to methods comprising the use of agents that specifically target the activity of the particular components of the mechanism identified by the applicants. Although subsequent dependent claims such as claim 2 characterise the feedback mechanism by defining it as a mechanism controlling the activity of a range of transport proteins other than ENaC, this simply further characterises the previously identified mechanism and does not alter the scope of the claims. The claims still define the same feedback mechanism that controls the activity of ENaC, they simply characterise it as a mechanism that also controls the activity of further $Na^+$ transport proteins. This further characterisation does not alter the scope of claims such as claims 2, 14 and 20.

Furthermore, with claims such as 3-6 and 10-12, although these claims are narrower in scope because they define specific agents, these agents are known, or at least suspected (see D2-D4 and D7) as modulators of the pathway and are not agents that specifically interact with the features of the pathway identified for the first time by the applicants. Therefore, the claims simply define the use of agents that will interact with the known components of the known inhibitory feedback mechanism. The scope of the claims will only be altered to reflect the applicant's invention if the claims are limited to the use of agents that specifically interact with the 'new' components of the pathway identified by the applicant, ie $Na^+$ transport proteins other than ENaC and the intracellular $Na^+$ receptors GILT and SCunique.

Continued in supplemental box 2.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/AU00/00980

**Supplemental Box**
(To be used when the space in any of the preceding boxes is not sufficient)

**Continuation of Box V2**

D1 also discusses the mutations involved in Liddle's syndrome and the fact that they correspond to mutations in ENaC that alter the sites associated with ubiquitination and inactivation of ENaC sodium transport. All of the citations also discuss amiloride and its analogues as inhibitors of cytosolic sodium regulation. As such all of the documents disclose the presence of a negative feedback mechanism regulating intracellular sodium concentrations and make it clear that the mechanism extends beyond ENaC and involves a range of intracellular proteins, including Nedd4, $G_o$ and ubiquitin.

All of the citations also recognise that there are a range of diseases, such as Liddle's syndrome, associated with inappropriate cytosolic sodium levels, that are caused by altered regulation of elements of the intracellular sodium regulation pathway.

On reading any one of D1-D4 or D7 a skilled engineer would readily appreciate the potential of inhibitors and components of the sodium negative inhibitory feedback system as tools for the treatment of diseases characterised by inappropriate activity of the specific inhibitory feedback mechanism described in the citations. Furthermore, given the information provided in any one of the citations it would be routine to use a range of known inhibitors such as amiloride, G-protein inhibitors and ubiquitin ligase inhibitors, or a range of compounds such as variants of ENaC, $G_o$ and Nedd4 to treat conditions associated with abnormal cytosolic sodium levels resulting from altered activity of the $Na^+$ inhibitory feedback mechanism. As such the citations deprive claims 1-21 of an inventive step.

The attorney's arguments in his responses to both the first and second opinions have centred around the contention that none of the documents recognise that the inhibitory feedback mechanism controls the activity of $Na^+$ transport proteins other than ENaC. The examiner accepts this argument. However, the claims as presently drafted are not limited to methods comprising the use of agents that specifically target the 'new' components of the pathway identified by the applicants, those components being the intracellular $Na^+$ receptor as identified by SEQ ID NOS 2 and 4, and $Na^+$ transport proteins other than ENaC. Although the claims recite components such as $Na^+$ transport proteins, in particular NHE1, NHE2, NHE3, the $Na^+$-$HCO_3^-$ cotransporter and the $Na^+K^+2Cl$ cotransporter, they only recite these components in the context of features that further characterise the previously identified feedback mechanism, not as components that specifically interact with, and define the agents recited in the claims. Therefore the claims define nothing more than the previously defined feedback mechanism, albeit a more comprehensively characterised feedback mechanism and simply recite any agents that regulate the activity of this mechanism, regardless of whether they are specifically interacting with 'new' components of the mechanism or with previously identified components of the mechanism. As such, although claims that define methods comprising the use of agents that specifically target the intracellular $Na^+$ receptor or $Na^+$ transport proteins other than ENaC, for the purpose of modulating the activity of the specific inhibitory feedback mechanism identified by the applicant may be both novel and inventive, the claims as presently drafted do not define these features and as such do not adequately distinguish between the teachings of the prior art and the applicant's invention.

D5, D6 and D8 all disclose problems associated with inhibition of the $Na^+/H^+$ exchanger (NHE) during ischaemia and reperfusion. However they do not disclose an inhibitory feedback mechanism controlling the activity of NHE and therefore they do not disclose or teach toward the methods of claims 1-41.

As none of the documents disclose sequences with homology to SEQ ID NOS 1-4 or isolation of an intracellular $Na^+$ receptor, none of the documents deprive claims 22-41 of novelty or an inventive step.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/12805 A1

(51) International Patent Classification[7]: C12N 15/12, A61K 38/16, 48/00

(21) International Application Number: PCT/AU00/00980

(22) International Filing Date: 16 August 2000 (16.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PQ 2239 16 August 1999 (16.08.1999) AU

(71) Applicant *(for all designated States except US)*: **THE UNIVERSITY OF SYDNEY** [AU/AU]; Sydney, NSW 2006 (AU).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **COOK, David, Ian** [AU/AU]; 35 Bromborough Road, Roseville, NSW 2069 (AU). **FRALEY, Kristie-Ann** [AU/AU]; Unit 29, 6 Murray Street, Lane Cove, NSW 2066 (AU). **ISHIBASHI, Hajime** [JP/JP]; Sanbankan 1013, 6-1 Ka 3-chome, Nagareyama, Chiba 270-0176 (JP). **KOMWATANA, Permsak** [TH/AU]; 17/14-18 Bennett Street, Newton, NSW 2042 (AU). **SANCHEZ-PEREZ, Angeles** [AU/AU]; 1 Berowra Place, Belrose, NSW 2085 (AU). **YOUNG, John** [AU/AU]; 28/18 Eastbourne Road, Darling Point, NSW 2027 (AU). **DINUDOM, Anuwat** [TH/AU]; 17/14-18 Bennett Street, Newton, NSW 2042 (AU).

(74) Agent: **FB RICE & CO**; 139 Rathdowne Street, Carlton, VIC 3053 (AU).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *With international search report.*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 01/12805 A1

(54) Title: METHODS FOR DIAGNOSIS AND TREATMENT OF HUMAN DISEASES INCLUDING HYPERTENSION

(57) Abstract: Methods for diagnosis and treatment of human disease, particularly human disease characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of $Na^+$ transport proteins (e.g. hypertension), are disclosed. Additionally, the specification discloses novel $Na^+$ receptors and isolated DNA molecules encoding same.

# METHODS FOR DIAGNOSIS AND TREATMENT OF HUMAN DISEASES INCLUDING HYPERTENSION

## Field of the Invention:

The present invention relates to the diagnosis and treatment of human disease, particularly human disease characterised by abnormal cytosolic ion composition resulting from reduced or over activity of $Na^+$ transport proteins such as the ubiquitous $Na^+$-$H^+$ exchanger, NHE1.

## Background of the Invention:

In recent years, over activity of $Na^+$ transporting systems in absorptive epithelia has been implicated in the pathogenesis of a number of major diseases including hypertension (1, 2), diabetic nephropathy (3), cardiological syndrome X (4), ventricular hypertrophy (5), chronic pulmonary hypertension (6) and cystic fibrosis (7). In the case of the hereditary hypertensive disease known as Liddle's syndrome, this activity has been attributed to a mutation of the epithelial $Na^+$ channel leading to loss of an inhibitory feedback mechanism which normally switches off $Na^+$ channel activity in response to increased intracellular $Na^+$ (8, 9). The mechanisms that underlie this so-called homocellular regulation have been the subject of controversy, but recent experiments have revealed a previously unsuspected mechanism in which cytosolic $Na^+$ is "sensed" by an intracellular receptor (10). This receptor activates the G protein, $G_o$ (11), the $\alpha$-subunit of which then causes the ubiquitin-protein ligase, Nedd4 (10), to ubiquitinate and inactivate the epithelial $Na^+$ channels (12, 13). This receptor for intracellular $Na^+$ is blocked by amiloride and amiloride analogs such as dimethylamiloride and benzimidazole guanidinium (10), thus explaining the previously puzzling ability of these agents to stimulate $Na^+$ channel activity (14).

The present applicants have now found that the intracellular $Na^+$ receptor that controls absorptive epithelial $Na^+$ channels also controls the activity of the ubiquitous isoform of the $Na^+$-$H^+$ exchanger 1, NHE1 (34). This finding suggests that intracellular $Na^+$ receptors form part of a general mechanism for regulating $Na^+$ transport proteins. It is therefore anticipated that the intracellular $Na^+$ receptors (and the signal-transduction systems by which they control $Na^+$ channels, $Na^+$-$H^+$ exchangers and other $Na^+$

transporting proteins) shall provide a useful target for diagnostic assays and treatments for hypertension and other diseases.

**Disclosure of the Invention:**

Thus, in a first aspect, the present invention provides a method of treatment of a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a $Na^+$ transport protein, the method comprising administering to a subject having said disease an effective amount of an agent that substantially restores the ion composition of the cytosol in said diseased cells to that which is found in corresponding cells from healthy tissue.

Preferably, the present invention provides a method of treatment of a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a $Na^+$ transport protein other than an epithelial $Na^+$ receptor. Most preferably, the present invention provides a method of treatment of a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a $Na^+$ transport protein selected from those which are inactivated by ubiquitination (e.g. through the action of a ubiquitin-protein ligase) and, particularly, from those included in the group consisting of NHE1, $Na^+$-$H^+$ exchanger 2 (NHE2) (35), $Na^+$-$H^+$ exchanger 3 (NHE3) (36), the $Na^+$-$HCO_3^-$ cotransporter (37) and the $Na^+K^+2Cl$ cotransporter (38).

Where the characteristic abnormal cytosolic ion composition arises from reduced $Na^+$ transport protein activity resulting from, for example, $Na^+$ transport protein mutation (e.g. hereditary), depressed $Na^+$ transport protein expression or inappropriate activity of the $Na^+$ transport protein inhibitory feedback mechanism, the administered agent may be selected from gene therapy agents (e.g. recombinant adenoviruses capable of causing the expression of non-mutated $Na^+$ transport protein) and agents capable of blocking the $Na^+$ transport protein inhibitory feedback mechanism. Preferred agents of the latter kind are amiloride and amiloride analogs (e.g. 6-iodoamiloride, N-dimethylamiloride, and benzimidazoylguanidium), G-protein inhibitors (e.g. GDP-β-S (39) and NF023 (40)) and agents that inhibit the action of ubiquitin protein ligase on the $Na^+$ transport protein. Examples of this latter kind of agents are dominant negative mutants of ubiquitin (e.g.

K48R (24)), agents that prevent binding of the ubiquitin protein ligase to the $Na^+$ transport protein (e.g. membrane permeable peptide analogs of the protein motif to which the ubiquitin protein ligase binds such as the WW2 and WW3 domains of Nedd4 (10)), agents that prevent ubiquitination of the $Na^+$ transport protein (e.g. membrane permeable peptide analogs of the protein motif which is actually ubiquitinated, such as the N-terminal of the $\alpha$- or $\gamma$-subunit of ENaC (41)) and inhibitors of the effectors of ubiquitin action on the $Na^+$ transport protein including proteins involved in endocytosis (e.g. membrane permeable analogs of amphiphysin SH3 peptide(42)), and inhibitors of the degradation of the $Na^+$ transport protein by proteasomes (e.g. lactacystin) or lysosomes (e.g. bafilomycin or chloroquine). Peptide analogs may be made to be membrane permeant by including a *Drosophila* antennapedia homeobox domain (15, 16).

Where the characteristic abnormal cytosolic ion composition arises from $Na^+$ transport protein over activity resulting from, for example, $Na^+$ transport protein mutation (e.g. hereditary), loss of the $Na^+$ transport protein inhibitory feedback mechanism or inappropriate activity of other control systems (e.g. excessive levels of growth factors or glucose), the administered agent may be selected from gene therapy agents (e.g. adenoviruses capable of causing the expression of a protein participating in the $Na^+$ transport protein inhibitory feedback mechanism), intracellular $Na^+$ receptor activators (e.g. guanidium and guanidium analogs), G-protein activators (e.g. GTP-$\gamma$-S (43) and receptor mimetic peptides such as APP20(17)), ubiquitin ligase activators (e.g. membrane permeable peptides that mimic the effect of active G proteins on the ubiquitin protein ligase), and agents that trigger endocytosis.

An "effective amount" of the agent used in the method of the first aspect will depend upon the particular agent used, however, generally, the amount would be expected to be below about 10 mg/kg. For example, an effective amount of amiloride or an amiloride analog would typically be in the range of 1 to 3 mg/kg.

The agent may be formulated with various pharmaceutically-acceptable excipients and/or carriers commonly used in the art and prepared for administration orally (e.g. as tablets, capsules, caplets or liquids), nasally (e.g. aerosol sprays), rectally (e.g. as suppositries) and transdermally (e.g. as a transdermal patch or dermally absorbed cream or lotion). The agent may also

be formulated as an injectible solution or suspension for subcutaneous, intravenous or intramuscular administration.

In a second aspect, the present invention provides a method of diagnosis of a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a $Na^+$ transport protein, the method comprising isolating from a subject suspected of having said disease a sample of cells (such as epithelial cells or lymphocytes) and assessing said sample of cells for reduced or over activity of said $Na^+$ transport protein or its inhibitory feedback mechanism.

Preferably, the present invention provides a method of diagnosis of a human disease which is characterised by abnormal cytosolic ion composition resulting from reduced or over activity of a $Na^+$ transport protein other than an epithelial $Na^+$ receptor. Most preferably, the present invention provides a method of diagnosis of a human disease which is characterised by abnormal cytosolic ion composition resulting from reduced or over activity of a $Na^+$ transport protein selected from those which are inactivated by ubiquitination (e.g. through the action of a ubiquitin-protein ligase) and, particularly, from those included in the group consisting of NHE1, NHE2, NHE3, the $Na^+$-$HCO_3^-$ cotransporter and the $Na^+K^+2Cl$ cotransporters.

The sample of cells may be assessed for reduced or over activity of $Na^+$ transport protein by, for example, determining the rate of $Na^+$-dependent intracellular pH ($pH_i$) recovery and comparing the value against similarly measured values from cells from healthy tissue isolated from the said suffering subject or from a control (i.e. non-diseased) subject or subjects (e.g. an average value from a panel of two or more healthy subjects).

In a variation of the invention according to the second aspect, the sample of diseased cells may be assessed for over or under expression of the $Na^+$ transport protein or another protein participating in the $Na^+$ transport protein inhibitory feedback mechanism (e.g. by polymerase chain (PCR) techniques, Northern blot hybridisation, Western blot or immunoprecipitation).

In a third aspect, the present invention provides a method of diagnosis of a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a $Na^+$ transport protein, the method comprising isolating a genomic DNA sample from a subject suspected of having said disease and assessing said sample for

the presence of a gene encoding a mutated product causitive of said reduced or over activity of said $Na^+$ transport protein.

In a fourth aspect, the present invention provides a method of assessing a subject for a predisposition to a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a $Na^+$ transport protein, the method comprising isolating a genomic DNA sample from a subject and assessing said sample for the presence of a gene encoding a mutated product causitive of reduced or over activity of said $Na^+$ transport protein.

In the methods of the third and fourth aspects, the human disease is preferably one which is characterised by abnormal cytosolic ion composition resulting from reduced or over activity of a $Na^+$ transport protein other than an epithelial $Na^+$ receptor. Preferably, the $Na^+$ transport protein is selected from the group consisting of NHE1, NHE2, NHE3, the $Na^+$-$HCO_3^-$ cotransporter and the $Na^+K^+2Cl$ cotransport protein). The genomic DNA sample may be isolated using routine protocols known to the art. The genomic DNA sample may be isolated from any cell sample such as whole blood, tissue biopsy or cheek cell sample. The assessment of the presence of a gene encoding a mutated product causitive of reduced or over activity of the $Na^+$ transport protein, may be preferably achieved by hybridisation or PCR techniques using probes/primers designed to specifically hybridise to genes including mutated nucleotide sequences. The gene whose presence is to be assessed may encode a mutated $Na^+$ transport protein or a mutated protein participating in the $Na^+$ transport protein inhibitory feedback mechanism (e.g. a mutated G-protein or mutated intracellular $Na^+$ receptor).

The methods of the invention are applicable to, for example, hypertension, renal failure, cardiac hypertrophy and cardiological syndrome X.

The present applicants have also found that the intracellular $Na^+$ receptor controlling NHE1 is blocked by amiloride and amiloride analogs with the following order of potency:
6-iodoamiloride ($EC_{50}$ = 0.1 µmol/l) < amiloride (1.0 µmol/l) < 5-N-dimethylamiloride (30 µmol/l), benzamil (> 30 µmol/l) < benzimidazolylguanidium (300 µmol/l)

Knowledge of these differing potencies enables the isolation of a DNA molecule encoding the intracellular $Na^+$ receptor controlling NHE1. That is,

by using the α-subunit of $G_o$ as "bait" in a yeast two-hybrid technique ("The yeast two-hybrid system" edited by P.L. Bartel & S. Fields, Oxford University Press, Oxford, 1997), DNA molecules encoding interacting proteins may be isolated from suitable cDNA or genomic DNA libraries and then screened for the ability of the encoded proteins to bind 6-iodoamiloride. Further screens may be conducted for the relative inability of the encoded proteins to bind benzamil, the ability of antibodies raised to the encoded proteins to immunoprecipitate the α-subunit of $G_o$, and the ability of antibodies raised to the encoded proteins to block the NHE1 inhibitory feedback mechanism.

By using the yeast two-hybrid system with a constitutively active mutant of the α-subunit of $G_o$, it is possible to identify and isolate proteins which interact with active $G_o$ and hence are involved in the inhibitory feedback mechanism at a loci downstream of $G_o$. Similarly, by using the yeast two-hybrid system with a dominant negative mutant of the α-subunit of $G_o$, it is possible to identify and isolate proteins such as the intracellular $Na^+$ receptors which are involved in the inhibitory feedback mechanism at a loci upstream of $G_o$.

The present applicants have isolated 5 cDNA molecules from mouse kidney and mandibular gland cDNA libraries encoding likely intracellular $Na^+$ receptors controlling NHE1 and $Na^+$ channels. The 5 candidates are nucleobindin (18), GAIP (19), rap1GAP (20) and novel proteins designated GILT (formerly designated GILT) and SCunique.

Thus, in a fifth aspect, the present invention provides an isolated DNA molecule encoding an intracellular $Na^+$ receptor designated GILT, said DNA molecule comprising a nucleotide sequence substantially corresponding to that shown as SEQ ID NO: 1 or a nucleotide sequence showing ≥ 75% (more preferably ≥ 85%, most preferably ≥ 95%) homology to that shown as SEQ ID NO: 1.

Preferably, the isolated DNA molecule of the fifth aspect encodes a protein comprising an amino acid sequence substantially corresponding to that shown as SEQ ID NO: 2.

In a sixth aspect, the present invention provides an isolated DNA molecule encoding an intracellular $Na^+$ receptor designated SCunique, said DNA molecule comprising a nucleotide sequence substantially corresponding to that shown as SEQ ID NO: 3 or a nucleotide sequence showing ≥ 75%

(more preferably ≥ 85%, most preferably ≥ 95%) homology to that shown as SEQ ID NO: 3.

Preferably, the isolated DNA molecule of the sixth aspect encodes a protein comprising an amino acid sequence substantially corresponding to that shown as SEQ ID NO: 4.

The isolated DNA molecule of the fifth and sixth aspect may be incorporated into plasmids or expression vectors (including viral vectors), which may then be introduced into suitable bacterial, yeast, insect and mammalian host cells. Such host cells may be used to express the receptor encoded by the isolated DNA molecule.

Accordingly, in a seventh aspect, the present invention provides a mammalian, insect, yeast or bacterial host cell transformed with the DNA molecule of the fifth or sixth aspect.

In an eighth aspect, the present invention provides a method of producing an intracellular $Na^+$ receptor, comprising culturing the host cell of the seventh aspect under conditions enabling the expression of the DNA molecule and optionally recovering the expressed receptors.

Preferably, the host cell is mammalian, amphibian or of insect origin. Where the cell is mammalian, it is presently preferred that it be a Chinese hamster ovary (CHO) cell or human embryonic kidney 293 cell. Where the cell is of amphibian origin, it is presently preferred that it be a *Xenopus* oocyte. Finally, where the cell is of insect origin, it is presently preferred that it be an insect Sf9 cell.

In a ninth aspect, the present invention provides an intracellular $Na^+$ receptor designated GILT, said receptor comprising an amino acid sequence substantially corresponding to that shown as SEQ ID NO: 2, in a substantially pure form.

In a tenth aspect, the present invention provides a candidate intracellular $Na^+$ receptor designated SCunique, said receptor comprising an amino acid sequence substantially corresponding to that shown as SEQ ID NO: 4, in a substantially pure form.

In an eleventh aspect, the present invention provides an antibody which specifically binds to a receptor according to the ninth or tenth aspect. Such antibodies may be polyclonal or monoclonal and may be produced in accordance with any of the known techniques in the art.

The present applicants have also identified two variants of the nucleotide sequence encoding GILT (SEQ ID NO: 5 and SEQ ID NO: 6) and isolated and sequences some of the 5' non-coding sequence of the nucleotide sequence encoding SCunique (SEQ ID NO: 7). It is to be understood that the present invention extends to these additional nucleotide sequences.

In a twelfth aspect, the present invention provides a method for detecting agonist or antagonist agents of the receptor of the ninth or tenth aspect, comprising contacting said receptor, or a host cell transformed with and expressing the DNA molecule of the fifth or sixth aspect, with a test agent under conditions enabling the activation of said receptor, and detecting an increase or decrease in activity of the receptor.

In a further aspect, the present invention provides a nucleic acid probe/primer comprising a nucleotide sequence of 10 or more nucleotides capable of specifically hybridising to a unique sequence within a DNA molecule having a nucleotide sequence as shown as SEQ ID NO: 1 or SEQ ID NO: 3 under high stringency conditions.

As used herein, the term "high stringency conditions" refers to conditions that (i) employ low ionic strength and high temperature for washing, for example, 15 mM NaCl/1.5 mM sodium citrate/0.1% $NaDodSO_4$ at 50°C; (ii) employ during hybridisation a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42°C; or (iii) employ 50% formamide, 5 x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS and 10% dextran sulfate at 42°C in 0.2 x SSC (30 mM NaCl, 3 mM sodium citrate) and 0.1% SDS.

The term "substantially corresponding" as used herein in relation to nucleotide sequences is intended to encompass minor variations in the nucleotide sequence which due to degeneracy in the DNA code do not result in a change in the encoded protein. Further, this term is intended to encompass other minor variations in the sequence which may be required to enhance expression in a particular system but in which the variations do not result in a decrease in biological activity of the encoded protein.

The term "substantially corresponding" as used herein in relation to amino acid sequences is intended to encompass minor variations in the

amino acid sequences which do not result in a decrease in biological activity of the encoded protein. These variations may include conservative amino acid substitutions. The substitutions envisaged are:-

G, A, V, I, L, M; D, E; N, Q; S, T; K, R, H; F, Y, W, H; and P, Nα-alkylamino acids.

References to percent homology values herein are calculated by the BLAST program blastn as described by Altschul, S.F. et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Research Vol. 25, No. 17, pp 2289-3402 (1997).

The terms "comprise", "comprises" and "comprising" as used throughout the specification are intended to refer to the inclusion of a stated step, component or feature or group of steps, components or features with or without the inclusion of a further step, component or feature or group of steps, components or features.

The invention will hereinafter be further described by way of the following non-limiting example and accompanying figures.

**Brief description of the accompanying figures:**

Figure 1: Shows features of the $Na^+$-dependent $pH_i$ recovery measured with a zero $Na^+$ pipette solution. (A) Representative experiment with 10 mM ATP in the pipette. The bar indicates the period of readmission of 155 mM $Na^+$ solution to the bath. (B) Concentration-response relation for the effect of extracellular ethylisopropylamiloride (EIPA) on the $Na^+$-dependent $pH_i$ recovery. (C) The effect of modifying intracellular ATP levels.

Figure 2: Shows inhibition of $Na^+$ -dependent $pH_i$ recovery by cytosolic $Na^+$. (A) Dependency of the $Na^+$-dependent $pH_i$ recovery on pipette $Na^+$. (B) The effects of inclusion of 20 mM $NMDG^+$ in the zero $Na^+$ pipette solution, or by buffering intracellular and extracellular $Ca^{2+}$ to zero by the inclusion of 20 mM 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetate (BAPTA) in the pipette solution and 1 mM EGTA in the bath solution. No $Ca^{2+}$ was added to either solution.

Figure 3: Shows that the $Na^+$ feedback inhibition is mediated by a G protein. (A) The effect of the addition of 100 μM GDP-β-S to the pipette solution. (B) The effect of the addition of 500 ng/ml activated pertussis toxin to the pipette solution. (C) The effect of the addition to the pipette solution of antibodies directed against various G protein α-subunits [$AbG_{i1, i2}$ = against

C terminals of $G\alpha_{i1}$ and $G\alpha_{i2}$; $AbG_{o,i3}$ = against C terminals of $G\alpha_o$ and $G\alpha_{i3}$; $AbG_{i3}$ = against C terminal of $G\alpha_{i3}$; $AbG_o$ = against N terminal of $G\alpha_o$; all 1 in 200 (vol/vol)].

Figure 4: Shows the inhibition of $Na^+$ feedback by intracellular amiloride. (A) Concentration-dependency of the effect of intracellular amiloride when included in 20 mM $Na^+$ solution. (B) The effect of the inclusion of 0.2 μM activated recombinant α-subunit of $G_o$ (act $G_o$) and amiloride (10 and 30 μM) in the zero $Na^+$ pipette solution. AS and inact $G_o$ denote controls in which activation solution or inactive $G\alpha_o$, respectively, were added to the pipette solution. (C) The effect of the inclusion of anti-Nedd4 antibody (A-Nd4; 1 μg purified 1gG/ml). GST-WW fusion protein (G-W; 0.3 mg/ml). GST-wild type-ubiquitin (wt; 0.3 mg/ml) or GST-dominant negative-ubiquitin (K48R) fusion protein (dn; 0.3 mg/ml) in the 20 mM $Na^+$ pipette solution. In A and C the broken lines indicate the mean rate of $pH_i$ recovery observed with zero $Na^+$ pipette solution.

Figure 5: Shows the mechanisms of feedback inhibition by intracellular $Na^+$ of epithelial $Na^+$ channels in salivary duct (absorptive) cells (A) and $Na^+$-$H^+$ exchange in salivary endpiece (secretory) cells (B). In each cell model, the apical membrane is on the left and the sodium pump ($Na^+$, $K^+$ ATPase) is shown in the basolateral membrane on the right.

**Example 1: Control of $Na^+$-$H^+$ exchange in salivary secretory cells by an intracellular $Na^+$ receptor.**

*Materials and Methods.*

Cell Preparation. Male Quackenbush strain mice were killed by cervical dislocation, and the mandibular glands were removed, finely minced, and incubated for 12 min in a physiological salt solution containing 1 mg/ml collagenase (Worthington type IV). The cell suspension was then dispersed by trituration and washed with fresh $Na^+$ rich bath solution containing 145 mM NaCl, 5.5 mM KCl, 1.2 mM $MgCl_2$, 7.5 mM Na-Hepes, 7.5 mM H-Hepes, 1 mM $CaCl_2$ and 10 mM glucose; the pH was adjusted to 7.4 with NaOH. The cells were filtered through a 75-μm nylon mesh and kept on ice until required.

Patch-Clamp Techniques. A technique based on that of Demaurex and coworkers (21) was used in which the whole-cell patch-clamp technique is used to control cytosolic composition while the pH-sensitive dye, BCECF, is

used to measure intracellular pH ($pH_i$). The patch-clamp techniques used were are described (22), and the cells were loaded with BCECF by including it in the pipette solution. Except for the experiments summarised in Figure 1C, in which $MgSO_4$ replaced MgATP, pipettes were filled with solutions containing 145 mM K-glutamate and Na-glutamate combined, 5 mM KCl, 5 mM Mes, 10 mM Mg-ATP, 1 mM EGTA, 40 mM sucrose, and 0.2 mM BCECF; the pH was adjusted to 6.0.

Measurement of $pH_i$. The equipment used to measure $pH_i$ was as described (23). The chamber (0.3 ml) was continuously perfused with a $Na^+$-free bath solution containing 145 mM *N*-methyl-D-glucamine (NMDG)-Cl, 5.5 mM KCl, 15 mM H-Hepes, 1.2 mM $MgCl_2$, 1 mM $CaCl_2$, and 10 mM glucose with a pH of 7.4. Single cells in the whole-cell configuration were voltage-clamped at -30 mV. After 3 min they were illuminated alternately at 490 and 430 nm. $Na^+$-$H^+$ exchange activity was measured by reintroducing $Na^+$ to the bath between 2 and 3 min after the start of illumination. $pH_i$ recovery rate was determined by fitting a linear regression to the linear phase of the $pH_i$ recovery (i.e., between 20% and 80% of maximal recovery). Calibration of the BCECF signal was by the nigericin high-$K^+$ method (23).

Chemicals. Sources of chemicals and the methods for activating pertussis toxin and G protein α-subunits were as reported (24, 25). Antibodies directed against the C terminals of the α-subunits of $G_{i1}/G_{i2}$, $G_{i3}$ and $G_{i3}/G_o$ were obtained from Calbiochem, and antibodies against the N-terminal of the α-subunit of $G_o$ were obtained from DuPont-NEN. They were used in the pipette solution at a 1 in 200 (vol/vol) dilution of the solution provided by the manufacturer. Glutathione-S-transferase (GST)-WW (G-W), GST-dominant negative-ubiquitin (K48R), and GST-wild type-ubiquitin fusion proteins were produced as described (24). The anti-Nedd4 antibody (A-Nd4) was purified IgG raised in rabbits against the C-terminal half of the protein (24, 26).

Results are presented as means ± SEM. At least five cells were tested in each experimental group. Statistical significance was assessed by using Student's unpaired t test. All experiments were performed at 22°C.

*Results.*

Activity of $Na^+$-$H^+$ exchangers was measured by a technique described by Demaurex and coworkers (21) in which the whole-cell configuration of the patch-clamp technique is used to control cytosolic composition while the pH-

sensitive dye, BCECF, measures $pH_i$. The cells were bathed initially in a zero $Na^+$ solution so that they would be unable to oppose the acid load imposed by the pipette solution using $Na^+$-dependent $H^+$ transporters such as the $Na^+$-$H^+$ exchanger. The bath solution then was changed to one containing 155 mM $Na^+$ so as to activate the $Na^+$-$H^+$ exchanger and cause $pH_i$ to recover toward normal levels (Fig 1A). The rate of this $Na^+$-dependent $pH_i$ recovery was used to estimate $Na^+$-$H^+$ exchange activity. The technique was validated by demonstrating that $Na^+$-dependent $pH_i$ recovery has features consistent with its being the result of the NHE1 isoform of $Na^+$-$H^+$ exchanger, which predominates in salivary secretory cells. It was found that the $Na^+$-dependent $pH_i$ recovery was highly sensitive to the amiloride analog, ethylisopropylamiloride (Fig. 1B), and that the recovery depended on the presence of ATP (21), being inactivated when intracellular ATP was depleted by treatment with 2-deoxy-D-glucose (5 mM) and oligomycin (5 μg/ml; Fig. 1C).

It was demonstrated that the rate of the $Na^+$-dependent $pH_i$ recovery declined with increasing pipette $Na^+$ concentration (Fig. 2A) in a manner similar to that described in sheep F2 Purkinje fibres (27). This inhibition evidently was caused by increased $[Na^+]_i$, because it could not be reproduced by the large organic cation, $NMDG^+$ (Fig. 2B). Because intracellular free $Ca^{2+}$ is known to regulate $Na^+$-$H^+$ exchangers (28), an investigation was made to determine whether a change in free intracellular $Ca^{2+}$ concentration could mediate this phenomenon. It was found that buffering cytosolic and extracellular $Ca^{2+}$ to nominal zero did not alter the effect of increased $[Na^+]_i$ (Fig. 2B).

An investigation was also made to determine the mechanism by which $[Na^+]_i$ controls the activity of the $Na^+$-$H^+$ exchanger. It was found that inclusion of the pipette solution of 100 μM GDP-β-S (which competitively inhibits the binding of GTP by G proteins; ref. (29) or of 500 ng/ml activated pertussis toxin (which ADP ribosylates G proteins of the $G_i$ and $G_o$ classes so as to prevent their interaction with receptors; ref. (30), reversed the inhibitory effect of 20 mM $Na^+$ (Fig. 3A and B). The ability of these agents to overcome the inhibitory effect of raised intracellular $Na^+$ completely without altering the electrochemical gradient for $Na^+$ indicates that the inhibition is not caused by a decreased electrochemical driving force for $Na^+$-$H^+$ exchange. Rather, it must be caused by a G protein-mediated feedback

pathway. In this regard, it was further found that inclusion in the pipette solution of antibodies directed against the α-subunit of the $G_o$ protein, which is known to be expressed in salivary endpiece cells (31), abolished the inhibitory effect of 20 mM $Na^+$. In contrast, antibodies directed against the α-subunits of $G_{i1}$, $G_{i2}$, and $G_{i3}$ were without effect (Fig. 3C).

In the absorptive cell of the salivary duct, $[Na^+]_i$ is sensed by a receptor the effect of which is mediated by $G_o$ (10). This receptor is blocked by amiloride and amiloride analogs such as dimethylamiloride and benzimidazolylguanidinium, thus explaining the ability of these agents to stimulate $Na^+$ channel activity. It was found that the inclusion of amiloride in the pipette solution reversed the inhibitory effect of 20 mM $Na^+$ (Fig. 4A). Further, it was found that the inclusion of the activated α-subunit of $G_o$ in the zero $Na^+$ pipette solution (Fig. 4B) inhibited the $Na^+$-$H^+$ exchanger and that the inclusion of as much as 30 μM amiloride in the pipette solution was unable to overcome this inhibition (Fig. 4B). Thus, amiloride exerts its inhibitory action upstream of $G_o$, presumably at the putative receptor for intracellular $Na^+$.

*Discussion.*

It has been previously shown that $[Na^+]_i$ and the G protein, $G_o$, regulate the activity of the epithelial $Na^+$ channel in the duct cells of the mouse mandibular gland via Nedd4 (24), a ubiquitin-protein ligase that is believed to bind to $Na^+$ channels and regulate their activity by ubiquitinating them (12, 13). Here, it was found that feedback inhibition of the $Na^+$-$H^+$ exchanger was not prevented by inclusion in the pipette solution of an antibody directed against Nedd4 or of a fusion protein composed of GST and the three WW-domains of mouse Nedd4 (GST-W), which acts as a dominant negative mutant of Nedd4 (Fig. 4C). This finding is consistent with the low level of expression of Nedd4 in endpiece cells (24). Feedback inhibition was blocked, however, by inclusion of a dominant negative mutant of ubiquitin (K48R) (24) in the pipette solution (Fig. 4C), indicating that feedback regulation of the exchanger nevertheless is mediated by ubiquitination. Because our preliminary data show that NHE1 transfected into COS cells is ubiquitinated (data not shown), the findings indicate that feedback regulation of NHE1 is mediated by ubiquitination of the exchanger protein. The control system then would resemble the control of surface expression of epithelial $Na^+$ channels by ubiquitination of the channel protein catalysed by Nedd4.

It cannot be excluded however, that the inactivation of NHE1 produced by $Na^+$ feedback is the result of ubiquitination of a protein associated with the exchanger, as recently has been proposed for the control of the growth hormone receptor by ubiquitination (32). Whatever the mechanism, the present findings taken together with the finding that activity of epithelial $Na^+$ channels can be rapidly down-regulated by ubiquitination suggest that ubiquitination may be a general mechanism for the rapid control of membrane transport protein activity.

**Example 2: Prevention of the progression of diabetic nephropathy and other forms of chronic renal failure by 6-iodoamiloride.**

*Materials and methods.*

20 mg 6-iodoamiloride tablets may be formulated and taken orally at a dosage of one or two every 6 hours.

*Discussion.*

6-iodoamiloride acts by blocking the intracellular $Na^+$ receptor that controls NHE1 and other sodium-dependent transporters as well as mediating the normal cellular responses to increased intracellular sodium concentration (which include release of cytokines and increased cell growth and proliferation (44). In this way, cytokine release and cellular proliferation caused by increased intracellular sodium can be treated with 6-iodoamiloride to prevent the cytokine release and cell growth and proliferation that lead to progression of renal failure.

**Example 3: Treatment of cells with reduced $Na^+$ transport with recombinant adenovirus.**

*Materials and methods.*

Recombinant adenovirus. Recombinant adenovirus including an expressible gene encoding the $Na^+$ receptor, GILT may be prepared by routine molecular biology techniques (33). Particularly, the clone encoding GILT (SEQ ID NO:1) may be ligated to a suitable mammalian promoter sequence (e.g. CMV (45)) and inserted into a suitable vector for the transfer, by homologous recombination, of the recombinant GILT gene into an adenovirus as described by He et al. (46).

Administration. The recombinant adenovirus may be formulated and administered in accordance with known methods in the art. In particular,

the recombinant adenovirus may be formulated for administration as a nasal spray or intrabronchial spray or given intraveneously (47, 48) or direct injections of muscle or of organs (49). With administration to the respiratory tract (50), the recombinant adenovirus will preferably be administered at a dose of $10^9$ plaque forming units (pfu) at intervals between 2 and 4 weeks.

*Discussion.*

Upon infection of host diseased cells, the adenovirus will bring about the expression of functional GILT protein to decrease $Na^+$ transport and restore cytosolic ion composition to substantially that of corresponding healthy cells.

**Example 4: Prevention of the progression of chronic hypoxic pulmonary hypertension and other forms of pulmonary hypertension by 6-iodoamiloride and other inhibitors of the sodium receptor.**

*Materials and methods.*

20mg 6-iodoamiloride tablets may be formulated and taken orally at a dosage of 1 or 2 every 6 hours.

*Discussion.*

6-iodoamiloride acts by blocking the intracellular $Na^+$ receptor that controls NHE1 and other sodium-dependent transporters as well as mediating the normal cellular responses to increased intracellular sodium concentration (which include release of cytokines and increased cell growth and proliferation (44). In this way, cytokine release and cellular proliferation caused by increased intracellular sodium can be treated with 6-iodoamiloride to prevent the cytokine release and cell growth and proliferation that lead to progression of pulmonary hypertension due to chronic hypoxia (51).

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

**References:**

1. Cui Y, Su YR, Rutkowski M, Reif M, Menon AG, Pun RY (1997) Loss of protein kinase C inhibitor in the beta T594M varient of the amiloride-sensitive $Na^+$ channel. Proc Natl Acad Sci USA 94:9962-9966.

2. Lifton RP (1996) Molecular genetics of human blood pressure variation. Science 272:676-680.

3. Sweeney FP, Siczkowski M, Davies JE, Quinn PA, McDonald J, Krowlewski AS, Ng LL (1995) Phosphorylation and activity of $Na^+/H^+$ exchanger isoform 1 of immortalized lymphoblasts in diabetic nephropathy. Diabetes 44:1180-1185.

4. Gaspardone A, Ferri C, Crea F, F Versaci, Tomai F, Santucci A, Chiariello L, Gioffre PA (1998) Enhanced activity of sodium-lithium countertransport in patients with cardiac syndrome X: a potential link between cardiac and metabolic syndrome X. J. Am coll Cardiol. 32:2031-2034.

5. Neves PL, Faisca M, Gomes V, Cacodcar S, Bernardo I, Anunciada AI, Viegas E, Martins H, da Silva AM (1996) Risk factors for left ventricular hypertrophy: role of $Na^+$-$Li^+$ countertransport. Kidney Int. 55:S160-S162.

6. Quinn D.A., Du H.K., Thompson B.T., Hales C.A. (1998) Amiloride analogs inhibit chronic hypoxic pulmonary hypertension. Amer. J. Resp. Critical Care Med. 157:1263-1268.

7. Stutts MJ, Canessa CM, Olsen JC, Hanrick M, Cohn JA, Rossier BC, Boucher RC (1995) CFTR as a cAMP-dependent regulator of sodium channels. Science 269: 847-850.

8. Dinudom A, Harvey KF, Komwatana P, Young JA, Kumar S, Cook DI (1998) Nedd4 mediates control of an epithelial $Na^+$ channel in salivary duct cells by cytosolic $Na^+$. Proc Natl Acad Sci USA 95:7169-7173.

9. Kellenberger S, Gautschi I, Rossier BC, Schild L (1998) Mutations causing Liddle syndrome reduce sodium-dependent downregulation of the epithelial sodium channel in the *Xenopus* ooxyte expression system. J Clin Invest 101:2741-2750.

10. Komwatana P, Dinudom A, Young J. A. and Cook D. I. (1998) J. Membr. Biol 162:225-232.

11. Komwatana P, Dinudom A, Young J. A. and Cook, D. I (1996) Proc Natl Acad Sci USA 93:8107-8111.

12. Staub O, Dho S, Henry P. C., Correa J, Ishikawa T, McGlade J, and Rotin, D. (1996) EMBO J. 15, 2371-2380.

13. Staub O, Gautschi I, Ishikawa T, Breitschopf K, Ciecanover, A, Schild L, and Rotin D. (1997) EMBO J. 16:6325-6336.

14. Garty H., and Palmer L.G. (1997) Physiol Rev 77:359-396.

15. Cussac D., Vidal M., Leprince C., Lin W.Q., Cornille F., Tiraboschi G., Roque B.P. and Garbay C. (1999) A Sos-derived petidimer blocks the Ras signalling pathway by binding both the Grb2 SH3 domains and displays antiproliferative activity. FASEB Journal 13:31-38.

16. Hollinger E.P., Chittenden T. and Lutz R.J. (1999) Bak BH3 peptide antagonises Bcl-x2 function and induces apoptosis through cytochrome C-independent activation of caspases. J. Biol. Chem. 274:13298-13304.

17. Lang J., Nishimoto I., Okamoto T., Regazzi R., Kiraly C., Weller U., Wollheim C.B. (1995) Direct control of exocytosis by receptor-mediated activation of the heterotrimeric GTPases $G_i$ and $G_o$ or by expression of their active G $\alpha$ subunits. EMBO Journal 14:3635-3644.

18. Lin P., Le-Niculescu H., Hosfmeister R., McCaffery J.M., Jin M., Hennemann H., McQuistan T., De Vries L., Farquhar M.G. (1998) The mammalian calcium-binding protein, nucleobindin (CALNUC), is a Golgi resident protein. J. Cell. Biol. 141:1515-1527.

19. Berman D.M., Wilkie T.M., Gilman A.G. (1998) GAIP and RSG4 are GTPase-activating proteins for the $G_i$ subfamily of G protein alpha subunits. Cell 86:445-452.

20. Jordan J.D., Carey K.D., Stork P.J.S., Iyengar R. (1999) Modulation of Rap activity by direct interaction of Galphao with Rap1GTPase-activating protein. J. Biol. Chem. 274:21507-21510.

21. Demaurex N, Romanek, RR., Orlowski J, and Grinstein S. (1997) J. Gen. Physiol 109:117-128.

22. Dinudom A, Young JA., and Cook DI. (1993) J. Membr. Biol. 135, 289-295.

23. Steward MC., Poronnik P, and Cook DI. (1996) J. Physiol. (London) 494:819-830.

24. Dinudom A, Harvey K. F., Komwatana, P, Young J. A., Kumar, S, and Cook D. I. (1998) Proc Natl Acad Sci USA 95:7169-7173.

25. Dinudom A, Komwatana P, Young JA. and Cook DI. (1995) J. Physiol. (London) 487:549-555.

26. Kumar S, Harvey KF, Kinoshita M, Copland NG, Noda M. and Jenkins NA (1997) Genomics 40:435-443.

27. Wu ML and Vaughan Jones RD (1997) J. Mol Cell Cardiol 29:1131-1140.

28. Orlowski J and Grinstein S. (1997) J. Biol Chem 272:22373-22376.

29. Eckstein F., Cassel D., Levkovitz H, Lowe M. and Sclinger Z. (1979) J. Biol Chem 254:9829-9834.

30. Katada T. and Ui M. (1982) J. Biol Chem 257:7210-7216.

31. Watson EL, Olver C., D'Silva N., and Belton C. M. (1994) J. Histochem Cytochem 42:41-47.

32. Govers R, ten Broeke, T, van Kerkhof P, Schwartz AL. and Strous GJ. (1999) EMBO J. 18:28-36.

33. Sambrook J., Fritsch E.S. and Maniatis T. (1989) Molecular Cloning: a laboratory manual, Second Edition, Cold Spring Harbor Laboratory Press, USA.

34. Ishibashi H, Dinudom A, Harvey KF, Kumar S, Young JA and Cook DI (1999) Proc. Natl. Acad. Sci. USA 96:9949-9953.

35. Counillon L. and Pouyseggur J. (2000) J. Biol. Chem. 275:1-4.

36. Orlowski J. and Grinstein S. (1997) J. Biol. Chem. 272:22373-22376.

37. Romero M.F. and Boron W. (1999) Annu. Rev. Physiol. 61:699-723.

38. Haas M. and Forbush B 3rd (1998) J. Bioenerg. Biomembr. 30:161-172.

39. Komwatana P., Dinudom A., Young J.A. and Cook D.I. (1996) Proc. Natl. Acad. Sci. USA 93:8107-8111.

40. Friessmuth M., Beindl W., Nickel P., Ijzerman A.P., Hohenegger M. and Nanoff C. (1996) Mol. Pharmacol. 49:602-611.

41. Gautschi I., Ishikawa T., Breitschopf K., Ciechanover A., Schild L. and Rotin D. (1997) EMBO J 16:6325-6336.

42. Volchuk A., Narine S., Foster L.J., Grabs D., De Camilli P. and Klip A. (1998) Biol. Chem. 273:8169-8176.

43. Dinudom A., Komwatana P., Young J.A. and Cook D.I. (1995) J. Physiol. (london) 487:549-555.

44. Stanton B.A. and Kaissling B. (1989) Am. J. Physiol. 257:F1-F10.

45. Cummings MM, O'Mullane LM, Barden JA, Cook DI & Poronnik P. (2000) Cell Calcium 27: 247-255.

46. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW & Vogelstein BA. A simplified system for generating recombinant adenoviruses. Proc. Natl Acad. Sci. USA 95: 2509-2514, 1998.

47. Nemunatis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD,Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM , Walsh GL et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumours of patients with non-small-cell lung cancer. J. Clin. Oncol. 18: 609-622, 2000.

48. Dobrzynski E, Yoshida H, Chao J & Chao L. Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rat. Immunopharmacology 44: 57-65, 1999.

49. Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW & Crystal RG. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA. Ann. Surg. 230: 466-470, 1999.

50. Harvey BG, Leopold PL, Hackett NR, Grasso TM, Williams PM, Tucker AL, Kaner RJ, Ferris B, Gonda I, Sweeney TD, Ramalingam R, Kovesdi

I, Shak S & Crystal RG. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J. Clin. Invest. 104: 1245-1255, 1999.

51. Quinn DA, Du H-K, Thompson BT & Hales CA. Amiloride analogues inhibit chronic hypoxic pulmonary hypertension. Am. J. Resp. Crit. Care Med. 157: 1263-1268, 1998.

**Claims:**

1. A method of treatment of a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a $Na^+$ transport protein, the method comprising administering to a subject having said disease an effective amount of an agent that substantially restores the ion composition of the cytosol in said diseased cells to that which is found in corresponding cells from healthy tissue.

2. A method according to claim 1, wherein the $Na^+$ transport protein is other than an epithelial $Na^+$ receptor.

3. A method according to claim 1, wherein the $Na^+$ transport protein is selected from the group consisting of $Na^+$-$H^+$ exchanger 1 (NHE1), $Na^+$-$H^+$ exchanger 2 (NHE2), $Na^+$-$H^+$ exchanger 3 (NHE3), the $Na^+$-$HCO_3^-$ cotransporter and the $Na^+K^+2Cl$ cotransporter.

4. A method according to any one of claims 1-3, wherein the abnormal cytosolic ion composition in diseased cells arises from reduced $Na^+$ transport protein activity.

5. A method according to claim 4, wherein said agent is selected from gene therapy agents and blocking agents of the $Na^+$ transport protein inhibitory feedback mechanism.

6. A method according to claim 5, wherein said agent is a recombinant adenovirus including a nucleotide sequence encoding a non-mutated $Na^+$ transport protein which is other than a non-mutated epithelial $Na^+$ receptor.

7. A method according to claim 5, wherein the agent is selected from amiloride and amiloride analogs.

8. A method according to claim 5, wherein said agent is a G-protein inhibitor.

9. A method according to claim 8, wherein the G-protein inhibitor is selected from GDP-β-S and NF023.

10. A method according to claim 5, wherein said agent is a ubiquitin protein ligase inhibitor.

11. A method according to claim 10, wherein the ubiquitin protein ligase inhibitor is selected from dominant negative mutants of ubiquitin and agents that prevent binding of ubiquitin protein ligase to $Na^+$ transport proteins.

12. A method according to any one of claims 1-3, wherein the abnormal cytosolic ion composition in diseased cells arises from over activity of a $Na^+$ transport protein.

13. A method according to claim 12, wherein said agent is selected from gene therapy agents, intracellular $Na^+$ receptor activators; G-protein activators, ubiquitin ligase activators and endocytosis triggering agents.

14. A method according to claim 13, wherein said gene therapy agent is an adenovirus including a nucleotide sequence encoding a non-mutated protein which participates in the $Na^+$ transport protein inhibitory feedback mechanism.

15. A method according to claim 13, wherein said intracellular $Na^+$ receptor activator is selected from guanidium and guanidium analogs.

16. A method according to claim 13, wherein said G-protein activator is selected from GDP-γ-S and receptor mimetic peptides.

17. A method of diagnosis of a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a $Na^+$ transport protein, the method comprising isolating from a subject suspected of having said disease a sample of cells and assessing said sample of cells for reduced or over activity of said $Na^+$ transport protein or the $Na^+$ transport protein in inhibitory feedback mechanisms.

18. A method according to claim 17, wherein said $Na^+$ transport protein is other than an epithelial $Na^+$ receptor.

19. A method according to claim 17, wherein said $Na^+$ transport protein is selected from the group consisting of $Na^+$-$H^+$ exchanger 1 (NHE1), $Na^+$-$H^+$ exchanger 2 (NHE2), $Na^+$-$H^+$ exchanger 3 (NHE3), the $Na^+$-$HCO_3^-$ cotransporter and the $Na^+K^+2Cl$ cotransporter.

20. A method according to any one of claims 17 to 19, wherein the sample of cells is a sample of epithelial cells or lymphocytes.

21. A method according to any one of the claims 17 to 20, wherein the sample of cells is assessed for reduced or over activity of $Na^+$ transport protein by determining the rate of $Na^+$-dependent intracellular pH ($pH_i$) recovery and comparing said rate against similarly measured rates from cells from healthy tissue isolated from said subject or a control subject(s).

22. A method of diagnosis of a human disease which is characterised by abnormal cytosolic ion composition in diseased, the method comprising isolating from a subject suspected of having said disease a sample of cells and assessing said sample of cells for over or under expression of the $Na^+$ transport protein or another protein participating in the $Na^+$ transport protein inhibitory feedback mechanism.

23. A method of diagnosis of a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of a $Na^+$ transport protein, the method comprising isolating a genomic DNA sample from a subject suspected of having said disease and assessing said sample for the presence of a gene encoding a mutated product causative of said reduced or over activity of said $Na^+$ transport protein.

24. A method of assessing a subject for a predisposition to a human disease which is characterised by abnormal cytosolic ion composition in diseased cells resulting from reduced or over activity of $Na^+$ transport protein, the method comprising isolating a genomic DNA sample from a

subject and assessing said sample for the presence of a gene encoding a mutated product causative of said reduced or over activity of said $Na^+$ transport protein.

25. A method according to any one of claims 22 or 24, wherein the said $Na^+$ transport protein is other than an epithelial $Na^+$ receptor.

26. A method according to any one of claims 22 to 24, wherein said $Na^+$ transport protein is selected from the group consisting of $Na^+$-$H^+$ exchanger 1 (NHE1), $Na^+$-$H^+$ exchanger 2 (NHE2), $Na^+$-$H^+$ exchanger 3 (NHE3), the $Na^+$-$HCO_3^-$ cotransporter and the $Na^+K^+2Cl$ cotransporter.

27. A method according to any one of claims 1 to 26, wherein the said human disease is selected from hypertension, renal failure, cardiac hypertrophy and cardiological syndrome X.

28. An isolated DNA molecule encoding an intracellular $Na^+$ receptor designated GILT, said DNA molecule comprising a nucleotide sequence showing ≥ 75% homology to the nucleotide sequence shown as SEQ ID NO: 1.

29. A DNA molecule according to claim 28, wherein said DNA molecule comprises a nucleotide sequence showing ≥ 85% homology to the nucleotide sequence shown as SEQ ID NO: 1.

30. A DNA molecule according to claim 28, wherein said DNA molecule comprises a nucleotide sequence showing ≥ 95% homology to the nucleotide sequence shown as SEQ ID NO: 1.

31. A DNA molecule according to claim 28, wherein said DNA molecule comprises a nucleotide sequence substantially corresponding to that shown as SEQ ID NO: 1.

32. A DNA molecule according to claim 28, wherein said DNA molecule encodes a protein comprising an amino acid sequence substantially corresponding to that shown as SEQ ID NO: 2.

33. An isolated DNA molecule encoding an intracellular $Na^+$ receptor designated SCunique, said DNA molecule comprising a nucleotide sequence showing ≥ 75% homology to the nucleotide sequence shown as SEQ ID NO: 3.

34. A DNA molecule according to claim 33, wherein said DNA molecule comprises a nucleotide sequence showing ≥ 85% homology to the nucleotide sequence shown as SEQ ID NO: 3.

35. A DNA molecule according to claim 33, wherein said DNA molecule comprises a nucleotide sequence showing ≥ 95% homology to the nucleotide sequence shown as SEQ ID NO: 3.

36. A DNA molecule according to claim 33, wherein said DNA molecule comprises a nucleotide sequence substantially corresponding to that shown as SEQ ID NO: 3.

37. A DNA molecule according to claim 33, wherein said DNA molecule encodes a protein comprising an amino acid sequence substantially corresponding to that shown as SEQ ID NO: 4.

38. A host cell transformed with a DNA molecule according to any one of claims 28 to 37.

39. A method of producing an intracellular $Na^+$ receptor, comprising culturing the host cell of claim 38 under conditions enabling the expression of said DNA molecule and optionally recovering the expressed receptors.

40. An intracellular $Na^+$ receptor designated GILT, said receptor comprising an amino acid sequence substantially corresponding to that shown as SEQ ID NO: 2, in a substantially pure form.

41. An intracellular $Na^+$ receptor designated SCunique, said receptor comprising an amino acid sequence substantially corresponding to that shown as SEQ ID NO: 4, in a substantially pure form.

42. An antibody which specifically binds to a receptor according to claim 40 or 41.

43. A method for detecting agonist or antagonist agents of the receptor of claim 40 or 41, wherein said method comprises contacting said receptor, or a host cell transformed with and expressing the DNA molecule of any one of claims 28 to 37, with a test agent under conditions enabling the activation of said receptor, and detecting an increase or decrease in activity of the receptor.

44. A nucleic acid probe or primer comprising a nucleotide sequence of 10 or more nucleotides, wherein said probe or primer specifically hybridises to a unique sequence within the DNA molecule of claim 31 or 36 under high stringency conditions.

45. An isolated DNA molecule comprising a nucleotide sequence substantially corresponding to that shown as SEQ ID NO: 5.

46. An isolated DNA molecule comprising a nucleotide sequence substantially corresponding to that shown as SEQ ID NO: 6.

47. An isolated DNA molecule comprising a nucleotide sequence substantially corresponding to that shown as SEQ ID NO: 7.

Figure 1


A
Na+
7.2
6.8
6.4
6.0
pH
0
100
200
300
sec
B
0.016
0.012
0.008
0.004
0.000
pH recovery (units/sec)
0
0.01
0.1
1
10
EIPA (μM)
C
10 mM Mg-ATP
no ATP
0.015
0.010
0.005
0.000
pH recovery (units/sec)
2-deoxyglucose
+
oligomycin

Figure 2


A
pH recovery (units/sec)
0.010
0.005
0.000
0 5 10 15 20
pipette Na+ (mM)
B
20 mM Na+
Na+ -free
20 mM NMDG+
0.016
0.012
0.008
0.004
0.000
BAPTA
BAPTA

Figure 3


A
B
C
20 mM Na+
Na+-free
pH recovery (units/sec)
0.012
0.008
0.004
0.000
0.020
0.015
0.010
0.005
GDPβS
GDPβS
PTX
PTX

Figure 4


A
B
C
pH recovery (units/sec)
0.015
0.010
0.005
0.000
0.1
1.0
10.0
amiloride (μM)
control
AS
Inact $G_o$
10
30
amiloride (μM)
act $G_o$
A-Nd4
G-W
wt
K48R

Figure 5



## Sequence Listing:

<110> The University of Sydney

<120> Methods for diagnosis and treatment of human diseases including hypertension

<160> 7

<170> PatentIn Ver. 2.1

<210> 1
<211> 3186
<212> DNA
<213> Mus musculus

<400> 1
atggaggcct cctgtctaga gctggccctg gaaggggagc ggctgtgcaa ggcgggggac 60
ttcaaggcag gtgtggcttt cttcgaggct gctgtgcagg tgggcactga ggacctgaag 120
acactgagtg ccatctacag ccagctgggc aatgcctact tctacctgaa ggagtatgcc 180
cgggccctgc agttctacaa acatgacttg ctgctggcac ggaccattgg tgaccgcatg 240
ggggaggcca aggctagtgg gaacctgggc aacacactca gggccctagg ccgattcgat 300
gaggcaatcg tctgctgcca acgacacttg gacattgccc aggagcaggg ggacaaggtt 360
ggggaggcga gagcactcta caacattgga aatgtgtacc acgccaaggg caaacagctt 420
tcctggaatg ctgcacagga ccccgggcac ctgccacctg atgtccgcga gacactgcac 480
agggcctctg agttttatgg gaggaacctg tctttggtga aggaactagg cgaccgggcg 540
gcccagggca gggcctatgg caacctgggt aacacccact acctactggg aaacttcacg 600
gaggccacaa ccttccacaa agagcgcctg gccatcgcca aggagtttgg ggacaaggca 660
gctgagcgga gggcctacag caacctgggc aatgctcaca tcttcttggg gcgctttgat 720
gtggctgctg aacattacaa gaagacgctg cagctgtctc ggcagctccg ggaccaggca 780
gtggaggctc aggcttgcta cagcctgggc aacacctaca cactgctaca ggactacgag 840
cgtgctgctg agtaccacct gcggcaccta gtcattgccc aggagctggc tgatagggtg 900
ggagagggcc gagcatgctg gagcctgggg aacgcctatg tgtccatggg gagccctgca 960
caggccttga cctttgccaa gaaacatctg cagatctccc aggagattgg agaccgaaac 1020
ggagaactga cagcccgcat gaatattgcc cacctgcagc tggccctggg ccggctgact 1080
agcccagcag cagcggagaa gccagatctg gctggctatg aggcacaagg agcaagaccc 1140
aaacggacac agaggctgag tgccgagacc tgggacctgc tgcggctccc cctggaccgg 1200
gagcagaatg gagagaccca ccacacaggg gactggaggg gtccaggcag ggactcgctt 1260
cccctcccca tgaggagcag gaagtaccag gaaggtccag atgccattga gaggagaccc 1320
cgggagggta gtcactctcc actggacagt gctgatgtaa gggtacaggt gcctcgtacg 1380
ggtattccca gggccccgtc ttctgacgag gagtgtttct ttgacctgct gagtaagttc 1440
cagagcagtc gcatggatga ccagcgctgt cccctggagg aaggccaggc tggggctgct 1500
gaggccacag ctgccccatc cgtggaggat agagcagctc agtcctccgt gacagcttca 1560
ccacagacag aggagttctt tgacctcatt gccagctccc agagccgccg gctggacgac 1620
cagagggcta gcgtaggcag cctgcctggg ctacgcatca ccctcaacaa tgtggggcac 1680
ctccgaggcg acggggacgc ccaggagccg ggggatgagt ttttcaacat gcttatcaaa 1740
taccagtcct ccaggattga tgaccagcgc tgcccacccc ctgatgtgct gccccgtggc 1800
cctaccatgc ctgatgagga tttcttcagc cttatccaga gggtgcaggc taagcggatg 1860
gatgagcagc gtgtggacct tgctgggagt ccagagcaag aggccagtgg gctgcctgat 1920
ccccagcagc agtgtccacc gggtgccagc taaggcctcg cccctacagc cagccatacc 1980
ctactctgga ctctgtaggc tcacggttgt ccacagtggc catgatcccc caataagcca 2040
aatcttccca aggccatgat ggacagccag ctcagcccca gccccttccc actgagccag 2100
atggtgggtg cacaaggccc ccccatccca ggtggtgggt gcaggctaga gctgctatat 2160
gggggagggc atgcttctgt ccccatggat ctccacagct tcctgcaggc ctgccctgcc 2220
ctgccctagg ccgggccttc agcatgttgg ccccgagccc cggtgctgtc cagagtcttt 2280
tccctcaagc cctgccctgc caaatgtgaa actctgccaa ctctcccaag gcccccagag 2340
gggcttcaag gacttcttct ggtgggggct acagtgctaa ggcatcttct gtcccccagc 2400
tggtcctggg atggctatga aggaggtaca ctctgatctg cctcacgacc ccagggcagg 2460

cactatcctg gcctggctgt gcccaaccct gctgagggag attggcagct acaaagtcca 2520
gacaccctga cctggtagtc cccagccttg cacttggcct ttgaggaaag atggagcttg 2580
cccctggcag aggggagagg caggtctcca agcatagggt cttgtactag gagtgctgag 2640
ctctggctgg tagtggacgt tcatgaggga tcctctcaac tagatccttc agtcctctta 2700
gtgagcatct accttctatt actagggaga tgatatcttg gctttctccc caaggagggg 2760
tccatatctt aattggacac agggcactgt agttggggtg gagactcagc cagaactgcc 2820
ggggcatcca tgagacagac ccttcgggac cgtggtccta gttcttgcct acaagtccta 2880
taggtagccc tactggaggg ctctgtacaa ctgtctaacc cagggcctct tacccagagg 2940
gccagggcaa gggaaactga ggacccaact tctgagaggg agaggcaaca tcactctgag 3000
agcagaaaca gatactagag cacagggtct cgggcgggac atggtggccg ccccgcatac 3060
ttgaatgtac atgcgtattt attgcttaca tgtgtttgcc atgttgttca tgggtccttt 3120
ctgacccgag aggtacattt gttttgtttt acccaaaaat aaaagtctgc caagtgaaaa 3180
aaaaaa 3186

<210> 2
<211> 650
<212> PRT
<213> Mus musculus

<400> 2

Met Glu Ala Ser Cys Leu Glu Leu Ala Leu Glu Gly Glu Arg Leu Cys
1 5 10 15

Lys Ala Gly Asp Phe Lys Ala Gly Val Ala Phe Phe Glu Ala Ala Val
20 25 30

Gln Val Gly Thr Glu Asp Leu Lys Thr Leu Ser Ala Ile Tyr Ser Gln
35 40 45

Leu Gly Asn Ala Tyr Phe Tyr Leu Lys Glu Tyr Ala Arg Ala Leu Gln
50 55 60

Phe Tyr Lys His Asp Leu Leu Leu Ala Arg Thr Ile Gly Asp Arg Met
65 70 75 80

Gly Glu Ala Lys Ala Ser Gly Asn Leu Gly Asn Thr Leu Arg Ala Leu
85 90 95

Gly Arg Phe Asp Glu Ala Ile Val Cys Cys Gln Arg His Leu Asp Ile
100 105 110

Ala Gln Glu Gln Gly Asp Lys Val Gly Glu Ala Arg Ala Leu Tyr Asn
115 120 125

Ile Gly Asn Val Tyr His Ala Lys Gly Lys Gln Leu Ser Trp Asn Ala
130 135 140

Ala Gln Asp Pro Gly His Leu Pro Pro Asp Val Arg Glu Thr Leu His
145 150 155 160

Arg Ala Ser Glu Phe Tyr Gly Arg Asn Leu Ser Leu Val Lys Glu Leu
165 170 175

Gly Asp Arg Ala Ala Gln Gly Arg Ala Tyr Gly Asn Leu Gly Asn Thr
180 185 190

His Tyr Leu Leu Gly Asn Phe Thr Glu Ala Thr Thr Phe His Lys Glu
195 200 205

Arg Leu Ala Ile Ala Lys Glu Phe Gly Asp Lys Ala Ala Glu Arg Arg
210 215 220

Ala Tyr Ser Asn Leu Gly Asn Ala His Ile Phe Leu Gly Arg Phe Asp
225 230 235 240

Val Ala Ala Glu His Tyr Lys Lys Thr Leu Gln Leu Ser Arg Gln Leu
245 250 255

Arg Asp Gln Ala Val Glu Ala Gln Ala Cys Tyr Ser Leu Gly Asn Thr
260 265 270

Tyr Thr Leu Leu Gln Asp Tyr Glu Arg Ala Ala Glu Tyr His Leu Arg
275 280 285

His Leu Val Ile Ala Gln Glu Leu Ala Asp Arg Val Gly Glu Gly Arg
290 295 300

Ala Cys Trp Ser Leu Gly Asn Ala Tyr Val Ser Met Gly Ser Pro Ala
305 310 315 320

Gln Ala Leu Thr Phe Ala Lys Lys His Leu Gln Ile Ser Gln Glu Ile
325 330 335

Gly Asp Arg Asn Gly Glu Leu Thr Ala Arg Met Asn Ile Ala His Leu
340 345 350

Gln Leu Ala Leu Gly Arg Leu Thr Ser Pro Ala Ala Ala Glu Lys Pro
355 360 365

Asp Leu Ala Gly Tyr Glu Ala Gln Gly Ala Arg Pro Lys Arg Thr Gln
370 375 380

Arg Leu Ser Ala Glu Thr Trp Asp Leu Leu Arg Leu Pro Leu Asp Arg
385 390 395 400

Glu Gln Asn Gly Glu Thr His His Thr Gly Asp Trp Arg Gly Pro Gly
405 410 415

Arg Asp Ser Leu Pro Leu Pro Met Arg Ser Arg Lys Tyr Gln Glu Gly
420 425 430

Pro Asp Ala Ile Glu Arg Arg Pro Arg Glu Gly Ser His Ser Pro Leu
435 440 445

Asp Ser Ala Asp Val Arg Val Gln Val Pro Arg Thr Gly Ile Pro Arg
450 455 460

Ala Pro Ser Ser Asp Glu Glu Cys Phe Phe Asp Leu Leu Ser Lys Phe
465 470 475 480

Gln Ser Ser Arg Met Asp Asp Gln Arg Cys Pro Leu Glu Glu Gly Gln
485 490 495

Ala Gly Ala Ala Glu Ala Thr Ala Ala Pro Ser Val Glu Asp Arg Ala
500 505 510

Ala Gln Ser Ser Val Thr Ala Ser Pro Gln Thr Glu Glu Phe Phe Asp
515 520 525

Leu Ile Ala Ser Ser Gln Ser Arg Arg Leu Asp Asp Gln Arg Ala Ser
530 535 540

Val Gly Ser Leu Pro Gly Leu Arg Ile Thr Leu Asn Asn Val Gly His
545 550 555 560

Leu Arg Gly Asp Gly Asp Ala Gln Glu Pro Gly Asp Glu Phe Phe Asn
565 570 575

Met Leu Ile Lys Tyr Gln Ser Ser Arg Ile Asp Asp Gln Arg Cys Pro
580 585 590

Pro Pro Asp Val Leu Pro Arg Gly Pro Thr Met Pro Asp Glu Asp Phe
595 600 605

Phe Ser Leu Ile Gln Arg Val Gln Ala Lys Arg Met Asp Glu Gln Arg
610 615 620

Val Asp Leu Ala Gly Ser Pro Glu Gln Glu Ala Ser Gly Leu Pro Asp
625 630 635 640

Pro Gln Gln Gln Cys Pro Pro Gly Ala Ser
645 650

<210> 3
<211> 2566
<212> DNA
<213> Mus musculus

<400> 3
aaggaggaca ctgcctggct ggttagctag catcgccgct ccaagactag ccgctcagcg 60
accacagccg ggttgctcca ccttaagtcg gaggcgcctg tacacaccct tgggttcggc 120
tgctctccca gcatccctca cgcgtggacg ccgggcttcc ggacctgggc ggagccccgg 180
ggtttggccg attgcgtctt cccagcccaa gccttccagc acccggtgcc aggggccatg 240
gagccccggg cagttgcgga tgccttggag accggagagg aagatgcggt gacagaagct 300
ctgcggtcgt tcaaccggga gcattctcag agcttcacct tcgatgatgc ccagcaggag 360
gacaggaaga gactcgcaaa gctactggtc tccgtcctgg agcagggctt gtcaccaaag 420
caccgtgtca cctggctgca gactatccga atcctatccc gagaccgcag ctgcctggac 480
tcatttgcca gccgccagag cttacatgca ctagcctgct atgctgacat taccgtctca 540
gaggaaccca tcccacagtc cccagacatg gatgtcctcc tcgagtctct caaatgcctg 600
tgtaatcttg tgctcagcag tccaacagca cagatgctag cagcagaggc tcgcctggtg 660
gtgaggctag cggagcgtgt gggactgtac cgcaagagga gctatcccca cgaagtccag 720
ttctttgact tgaggctcct tttcctgcta acagcccttc gcacggatgt gcgccagcaa 780
ctgtttcagg agctgcacgg tgtacgcctg ctgactgatg cgctggaact aacactgggc 840
gtggccccca aagaaaaccc tccggtgatg cttccagccc aagagacgga gagggccatg 900
gagatcctca aagtgctctt taatatcacc tttgactctg tcaagaggga agttgatgag 960
gaagatgctg ccctttaccg gtacctgggg actcttctgc ggcactgcgt gatggttgaa 1020
gctgctgggg accgcacaga ggagttccac ggccacacgg tgaatctcct ggggaacttg 1080
cccctcaagt gtttggatgt gcttctggcc ctggagctcc acgaaggatc cttagagttc 1140
atgggagtta acatggatgt gatcagtgcc ctcctcgcct tcctagagaa acgtctgcac 1200
cagacccaca ggctgaagga atgtgtggca cctgtgctga acgtgttgac agaatgtgcc 1260
cgcatgcacc gtcctgccag gaagttcctg aaggcccagg tcctgccccc tctgagggat 1320
gtgaggactc ggcctgaggt gggggacctg cttcgaaaca agcttgtccg cctcatgaca 1380
cacctggata cagatgtgaa gagagtagct gccgagttcc tctttgtctt atgttctgaa 1440
agtgtgcccc gattcatcaa gtacacaggc tacgggaatg ctgccggcct cctggctgcc 1500
aggggcctca tggctggggg ccgacccgag ggccagtact cagaggacga ggacacggac 1560
acagaggagt acagggaagc caaggccagc atcaaccctg tgactggaag ggtggaggag 1620
aagccgccta atcctatgga aggcatgaca gaggagcaga aggaacatga ggccatgaag 1680

ctagtgaaca tgtttgacaa gctctccagg cacagagtca tccaacccat ggggatgagt 1740
cccaggggtc acctcacttc tctgcaagat gcgatgtgtg agacaatgga gggacagctc 1800
tcctcagacc ctgactcaga tcctgactga agatgccagc ggccttgctc cccttcagaa 1860
ctggtgctgc ttccagacat gtcctggggt gctgcctcaa gaagccacac ccctctccag 1920
ctggggagcc cttctctctc ctcctcacat ttctgtcatc tgcctttggt ccagtttcct 1980
gtgtttagga ctgtggtagt cttaccctct gtgaagacgg ggaaccccacc tttcatttcc 2040
acaagtgaag ttgtttcttg gatgtggctg cagccacgag cagaattgcc ctggcacata 2100
aatgaacatg cgtgtatgag ggtggtaatg gagcagggta cacatggtgt aagcatgact 2160
gggctggatg ccagcccaga gcccgtatgt ggggcatacg ctgtgtttca aacattttag 2220
aatctgttga aattgtttaa gtatgtcaga aaacacacca agcgtcatgg ttcctgcttc 2280
tggccccact gagcacaggg ctagtggcct cttcttaact ttttggtcct ggcgctgcca 2340
cccactgcag tatccgcata cccaagcctc actagttgtg acaactaact cagtcacaac 2400
cactggctta gtaattctgt gaaggcgaaa gtaagacaaa gtcaaatctg agattctgag 2460
gcacagaata caggagagtt tgggacaaga ctgtgtatgt gaagtagtca ggtgaaaggc 2520
tattaaacag aaactgattt caaaaaaaaa aaaaaaaaaa aaaaaa 2566

<210> 4
<211> 530
<212> PRT
<213> Mus musculus

<400> 4
Met Glu Pro Arg Ala Val Ala Asp Ala Leu Glu Thr Gly Glu Glu Asp
1 5 10 15

Ala Val Thr Glu Ala Leu Arg Ser Phe Asn Arg Glu His Ser Gln Ser
20 25 30

Phe Thr Phe Asp Asp Ala Gln Gln Glu Asp Arg Lys Arg Leu Ala Lys
35 40 45

Leu Leu Val Ser Val Leu Glu Gln Gly Leu Ser Pro Lys His Arg Val
50 55 60

Thr Trp Leu Gln Thr Ile Arg Ile Leu Ser Arg Asp Arg Ser Cys Leu
65 70 75 80

Asp Ser Phe Ala Ser Arg Gln Ser Leu His Ala Leu Ala Cys Tyr Ala
85 90 95

Asp Ile Thr Val Ser Glu Glu Pro Ile Pro Gln Ser Pro Asp Met Asp
100 105 110

Val Leu Leu Glu Ser Leu Lys Cys Leu Cys Asn Leu Val Leu Ser Ser
115 120 125

Pro Thr Ala Gln Met Leu Ala Ala Glu Ala Arg Leu Val Val Arg Leu
130 135 140

Ala Glu Arg Val Gly Leu Tyr Arg Lys Arg Ser Tyr Pro His Glu Val
145 150 155 160

Gln Phe Phe Asp Leu Arg Leu Leu Phe Leu Leu Thr Ala Leu Arg Thr
165 170 175

Asp Val Arg Gln Gln Leu Phe Gln Glu Leu His Gly Val Arg Leu Leu
180 185 190

Thr Asp Ala Leu Glu Leu Thr Leu Gly Val Ala Pro Lys Glu Asn Pro

195 200 205

Pro Val Met Leu Pro Ala Gln Glu Thr Glu Arg Ala Met Glu Ile Leu
210 215 220

Lys Val Leu Phe Asn Ile Thr Phe Asp Ser Val Lys Arg Glu Val Asp
225 230 235 240

Glu Glu Asp Ala Ala Leu Tyr Arg Tyr Leu Gly Thr Leu Leu Arg His
245 250 255

Cys Val Met Val Glu Ala Ala Gly Asp Arg Thr Glu Glu Phe His Gly
260 265 270

His Thr Val Asn Leu Leu Gly Asn Leu Pro Leu Lys Cys Leu Asp Val
275 280 285

Leu Leu Ala Leu Glu Leu His Glu Gly Ser Leu Glu Phe Met Gly Val
290 295 300

Asn Met Asp Val Ile Ser Ala Leu Leu Ala Phe Leu Glu Lys Arg Leu
305 310 315 320

His Gln Thr His Arg Leu Lys Glu Cys Val Ala Pro Val Leu Asn Val
325 330 335

Leu Thr Glu Cys Ala Arg Met His Arg Pro Ala Arg Lys Phe Leu Lys
340 345 350

Ala Gln Val Leu Pro Pro Leu Arg Asp Val Arg Thr Arg Pro Glu Val
355 360 365

Gly Asp Leu Leu Arg Asn Lys Leu Val Arg Leu Met Thr His Leu Asp
370 375 380

Thr Asp Val Lys Arg Val Ala Ala Glu Phe Leu Phe Val Leu Cys Ser
385 390 395 400

Glu Ser Val Pro Arg Phe Ile Lys Tyr Thr Gly Tyr Gly Asn Ala Ala
405 410 415

Gly Leu Leu Ala Ala Arg Gly Leu Met Ala Gly Gly Arg Pro Glu Gly
420 425 430

Gln Tyr Ser Glu Asp Glu Asp Thr Asp Thr Glu Glu Tyr Arg Glu Ala
435 440 445

Lys Ala Ser Ile Asn Pro Val Thr Gly Arg Val Glu Glu Lys Pro Pro
450 455 460

Asn Pro Met Glu Gly Met Thr Glu Glu Gln Lys Glu His Glu Ala Met
465 470 475 480

Lys Leu Val Asn Met Phe Asp Lys Leu Ser Arg His Arg Val Ile Gln
485 490 495

Pro Met Gly Met Ser Pro Arg Gly His Leu Thr Ser Leu Gln Asp Ala
500 505 510

Met Cys Glu Thr Met Glu Gly Gln Leu Ser Ser Asp Pro Asp Ser Asp

515 520 525

Pro Asp
530

<210> 5
<211> 69
<212> DNA
<213> Mus musculus

<400> 5
atggcgagcc cggccccgcc cgtggccgag gagctcccgg gcccggcctc caggcgcctc 60
tactccagg 69

<210> 6
<211> 201
<212> DNA
<213> Mus musculus

<400> 6
tgtactgtgg ctgcgtctgc agggtctgtc tggggtgacc ttggcatggt gtccctcttc 60
agaccagggt ccaggggtgc agaaaaactg ccaaggacac tgccatagtc tgcaccctga 120
catgttcctg ttccactgag ggtcacagct acgttttcaa gaagatttag agtggcctgg 180
agagaagagc agagacctgg g 201

<210> 7
<211> 787
<212> DNA
<213> Mus musculus

<400> 7
cagtcctgcg ctgtgggtgt tactcggagc aggtgttcag acccaaattt ggagcagagg 60
ctaggaacca gctcagtaaa tcagtcggat gcctctggcg ctgctaaatc caactggatg 120
gggaggacag gcagacccga aagagactgg tgaaggagac ggccggggcc tgccactgag 180
taggggcaga gccggttagc acggcgggtg acatcatcca ctggagcact gtttgtatgt 240
gtcactgtgg ggcaccgact cagctaagtg gcgtgcggac ctggctcccc gctacacagc 300
gctcatacgc ttctaacctc agacacgcct cggctggccg cccctccgtt gctcctctcg 360
cgggagtggc ttttccacgg gtgttcttca cttccttctc tgcaattttc ttgagaataa 420
ccgtattact ttggtggcta ttctttttag ataggtctgc tagtttctgc ctctcgagtg 480
ctgggattta agaaggcgtg cgtcactatg cccggctaac cacgtgcatt attttgacca 540
tccaagtggt tgtacttctc tttccctatt ccctatggaa gatgagctcc aaggcctgga 600
tcgcgagaat cgtcttcccc aactgattaa gcggccagga gccggcgctc ccttctttat 660
cacagtacgg ggacaagagc gtaaagagga cggtccacgc gcgggccaag ccacacccca 720
ctccccaccc tcccatccca ccccaccccc cgcctgccag gaactcgggc tagagaggag 780
ggctcga 787

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00980

**A. CLASSIFICATION OF SUBJECT MATTER**

Int. Cl. [7]: C12N 15/12; A61K 38/16, 48/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)
SEE ELECTRONIC DATABASE BOX BELOW

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
SEE ELECTRONIC DATABASE BOX BELOW

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
See extra sheet

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| PX | Takesono, A. et al (1999) "Receptor-independent activators of heterotrimeric G-protein signaling pathways" J. Biol. Chem. 274(47), pages 33202-5. See the entire document. | 28-32, 40, 45, 46 |
| PX | Ishibashi, H. et al (1999) $Na^+$-$H^+$ exchange in salivary secretory cells is controlled by an intracellular $Na^+$ receptor" Proc. Natl. Acad. Sci. USA 96, pages 9949-53 See the entire document | 3, 5-11, 14-16, 19, 26 |

[X] Further documents are listed in the continuation of Box C [X] See patent family annex

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

| Date of the actual completion of the international search | Date of mailing of the international search report |
|---|---|
| 19 October 2000 | 23 OCT 2000 |
| Name and mailing address of the ISA/AU<br>AUSTRALIAN PATENT OFFICE<br>PO BOX 200, WODEN ACT 2606, AUSTRALIA<br>E-mail address: pct@ipaustralia.gov.au<br>Facsimile No. (02) 6285 3929 | Authorized officer<br>**TERRY MOORE**<br>Telephone No : (02) 6283 2632 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00980

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| X | Harvey, K.F. et al (1999) "All three WW domains of murine Nedd4 are involved in the regulation of epithelial sodium channels by intracellular $Na^+$" J. Biol. Chem. 274(18), pages 12525-30<br>See in particular the discussion. | 5, 10, 11, 14 |
| X | Komwatana, P. et al (1998) "Activators of epithelial $Na^+$ channels inhibit cytosolic feedback control. Evidence for the existence of a G protein-coupled receptor for cytosolic $Na^+$" J. Membrane Biol. 162, pages 225-32<br>See in particular the discussion and figure 7. | 5, 7, 8, 15, 16 |
| X | Dinudom, A. et al (1998) "Nedd4 mediates control of an epithelial $Na^+$ channel in salivary duct cells by cytosolic $Na^+$" Proc. Natl. Acad. Sci. USA 95, pages 7169-73<br>See in particular the discussion and figure 4. | 5, 6, 10, 11, 14 |
| X | Cook. D.I. et al (1998) "Control of $Na^+$ transport in salivary duct eptithelial cells by cytosolic $Cl^-$ and $Na^+$" Eur. J. Morphology 36, Supplement ++pages 67-73<br>See in particular the summary and figure 8. | 5, 7-9, 14, 16 |
| X | Symons, J.D. et al (1998) "Na-H exchange inhibition with cariporide limits functional impairment caused by repetitive ischemia" J. Cardiovascular Pharmacology 32, pages 853-62<br>See the entire document. | 3, 5, 7 |
| X | EP A 726 254 (MITSUI TOATSU CHEMICALS, INC.) 14 August 1996<br>See page 2, line 120 - page 3, line 3 and claim 10. | 3, 5, 7 |
| X | Komwatana, P. et al (1996) "Cytosolic $Na^+$ controls an epithelial $Na^+$ channel via the $G_o$ guanine nucleotide-binding regulatory protein" Proc. Natl. Acad. Sci. USA 93, pages 8107-11<br>See in particular the discussion and figure 5. | 5, 7, 8, 9, 14, 16 |
| X | EP A 622 356 (SUMITOMO PHARMACEUTICALS CO., LTD.) 2 November 1994<br>See in particular page 3. | 3, 5, 7 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00980

**Box I** **Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos :
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos :
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

**Box II** **Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

See extra sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
3, 5-11, 14-16, 19, 26 and 28-47

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

☐ The additional search fees were accompanied by the applicant's protest.

☒ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00980

**Supplemental Box**
(To be used when the space in any of Boxes I to VIII is not sufficient)

**Continuation of Box No: II**

The international application contains 8 separate inventions. These are:

Invention 1. Regulating the activity of NHE1 for normalising cytosolic ion concentration.

Invention 2 Regulating the activity of NHE2 for normalising cytosolic ion concentration.

Invention 3. Regulating the activity of NHE3 for normalising cytosolic ion concentration.

Invention 4. Regulating the activity of $Na^+HCO^-$ cotransporter for normalising cytosolic ion concentration.

Invention 5. Regulation the activity of $Na^+K^+2Cl^-$ cotransporter for normalising cytosolic ion concentration.

Invention 6. Regulating the activity of any $Na^+$ receptor for normalising cytosolic ion concentration.

Invention 7. Sequences 1, 2, 5 and 6 defining GILT sequences and variants.

Invention 8. Sequences 3, 4 and 7 defining SCunique sequences and non-coding regions thereof.

The feature linking inventions 1-6 resides in the regulation of $Na^+$ receptors for therapeutic use. However using epithelial $Na^+$ receptors for therapeutic use is already known. Thus a unity of invention does not exist *a posteriori*.

Inventions 7 and 8 are directed to the identification of new and alternative $Na^+$ receptors. The only common feature between these two inventions and inventions 1-6 is the $Na^+$ receptors. $Na^+$ receptors are already known (see above) and thus no unity exists *a posteriori*. There does not appear to be any common structural feature linking the two sequences defined in inventions 7 and 8 and thus there is no unity of invention *a priori* between these two groups of sequences.

The ISA searched inventions 7 and 8 under one search fee as it does not seem that significant extra effort is involved in combining these two inventions.

An additional search fee was paid and inventions 1-5 were searched under this search fee because it appeared that a single search could be drafted that would encompass all 5 inventions.

As a result the two searches covered the material defined in claims 3, 5-11, 14-16, 19, 26 and 28-47.

**Continuation of Box No: B**

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Medline, CA, GenPept, SwissProt, EMBL, Genbank: Sequences 1-7, keywords: GILT, SCunique, NHE1, NHE2, NHE3, Na+/H+ exchanger, Na+HCO- cotransporter, NaKCl cotransporter, sodium channel, cytosolic, intracellular, inhibition, feedback, regulation

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU00/00980

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

| Patent Document Cited in Search Report | | Patent Family Member | | | | | |
|---|---|---|---|---|---|---|---|
| EP | 622 356 | JP | 7010839 | CN | 1106800 | CA | 2121391 |
| EP | 726 254 | US | 5 627 193 | JP | 8277269 | | |

END OF ANNEX